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Abstract
Background Remethylation defects are rare inherited disor-
ders in which impaired remethylation of homocysteine to me-
thionine leads to accumulation of homocysteine and perturba-
tion of numerous methylation reactions.
Objective To summarise clinical and biochemical characteris-
tics of these severe disorders and to provide guidelines on
diagnosis and management.
Data sources Review, evaluation and discussion of the med-
ical literature (Medline, Cochrane databases) by a panel of
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experts on these rare diseases following the GRADE
approach.
Key recommendations We strongly recommend measuring
plasma total homocysteine in any patient presenting with the
combination of neurological and/or visual and/or haematolog-
ical symptoms, subacute spinal cord degeneration, atypical
haemolytic uraemic syndrome or unexplained vascular throm-
bosis. We strongly recommend to initiate treatment with par-
enteral hydroxocobalamin without delay in any suspected
remethylation disorder; it significantly improves survival
and incidence of severe complications. We strongly recom-
mend betaine treatment in individuals with MTHFR deficien-
cy; it improves the outcome and prevents disease when given
early.
Introduction
This guideline development process was initiated within
the frame of the BEuropean network and registry for
homocystinurias and methylation defects^ (E-HOD) pro-
ject, which was started in February 2013. The main
aims of the project are the formation of a sustainable
international collaboration of experts and clinically ac-
tive centres, development of guidelines and establish-
ment of a disease registry for homocystinurias and
methylation defects. Given the often significant delays
in diagnosis and the absence of standardised treatment
protocols, the evaluation of the published knowledge
and delineation of guidelines for diagnosis and treat-
ment of these rare diseases are urgently needed. Most
of the existing studies and reports are non-systematic,
observational studies, case series or case reports, which
are generally considered to be low quality evidence.
However, following collation of the available evidence
some very consistent patterns evolved. Confirmation and
validation of our observations by insights gained from
other fields of research (e.g. vitamin B12 deficiency in
the elderly) additionally informed our interpretation of
the evidence.
Homocysteine (Hcy) is an amino acid formed from methi-
onine (Met). Under normal circumstances Hcy is converted
into cysteine (transulfuration pathway) or remethylated
(remethylation pathway) forming Met.
All genetic remethylation defects share deficient ac-
tivity of methionine synthase due to various reasons:
decreased function of the methionine synthase enzyme
protein itself or of the associated enzyme methionine
synthase reductase; deficient production of the cofactor,
methyl-cobalamin; or disturbed supply of the substrate
methyl-tetrahydrofolate (MTHF). Some genetic disorders
of intracellular cobalamin (cbl) transport and processing
(cblC, cblD-MMA/Hcy, cblF and cblJ) cause deficient
synthesis not only of methylcobalamin but also of
adenosylcobalamin, the cofactor for methylmalonyl-
CoA mutase. Those combined remethylation disorders
are associated with increased Hcy and methylmalonic
acid (MMA). 5,10-methylenetetrahydrofolate reductase
(MTHFR) deficiency leads to impaired provision of 5-
MTHF resulting in decreased function of methionine
synthase (Fowler 2005) (Fig. 1).
Our understanding of the pathophysiology of the
remethylation disorders and MTHFR deficiency is incom-
plete. At present, there are five main hypotheses: (A) direct
toxicity of metabolites, (B) missing products, (C) impaired
methylation capacity, (D) oxidative stress, (E) impaired non-
enzymatic protein functions.
(A) Hyperhomocysteinaemias are predominantly associat-
ed with neurocognitive and vascular pathology.
Homocysteine and its metabolic product, homocysteic
acid, have been implicated in provocation of seizures
in rats (Kubová et al 1995; Mares et al 1997).
Besides its impact on renal function, accumulation
of MMA along with dicarboxylic acids like 2-
methylcitrate and propionyl-CoA have been found to
induce synergistic mitochondrial dysfunction (Morath
et al 2008; Zsengellér et al 2014).
(B) Impaired methionine synthase activity with accu-
mulation of intracellular 5-MTHF (folate trap) and
subsequent disruption of nucleotide synthesis com-
promise rapidly proliferating tissues such as bone
marrow or epithelia. In MTHFR deficiency, this
trapping of folates is not found but 5-methylTHF
synthesis is impaired, resulting in low levels of
methyl-tetrahydrofolate (CH3-THF) in the central
nervous system of unknown significance (Schiff
and Blom 2012).
(C) Remethylation of homocysteine (Hcy) is an important
mechanism that maintains the methylation capacity of
the organism and removes excess Hcy. Methylation
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reactions such as DNAmethylation, creatine and myelin
synthesis utilise S-adenosylmethionine (SAM), a metab-
olite formed from Met as the methyl group donor.
Accordingly, any disorder or disruption of the Met-
Hcy-SAM pathway affects methylation capacity by
impairing multiple metabolic systems and processes
(King et al 2012; Surtees et al 1991).
(D) Enhanced oxidative stress due to a disturbance of gluta-
thione metabolism has been shown in patients with the
cblC defect and may contribute to the underlying path-
ophysiology (Pastore et al 2014).
(E) Recent data suggest that not only the accumulation of
metabolites but also the perturbed non-enzymatic func-
tions, e.g. of the MMACHC protein may add to the
pathophysiology behind the disease (Moreno-Garcia
et al 2014; Brooks et al 2016).
Methods
Panelists involved in the guideline process were invit-
ed by the EHOD project leaders according to their
expertise regarding the diseases in terms of biochem-
istry; genetics; clinical, psychosocial and laboratory
diagnosis and patient management and/or research
activities.
The PubMed and Cochrane databases were searched
using the following terms: remethylation defects OR se-
vere mthfr OR severe methylenetetrahydrofolate reduc-
tase OR cblc OR cbld OR cblf OR cblj OR cble OR
cblg OR methylmalonic aciduria homocystinuria OR
methylmalonic aciduria homocystinuria OR methylmalonic
acidemia homocysteinemia OR methylmalonic aciduria
homocysteinemia OR BCobalamin C OR Cobalamin D
OR Cobalamin E OR Cobalamin F OR Cobalamin G
OR Cobalamin J^ (last update February 2016: 834
publications).
The resulting list of publications was disposed of all
articles predominantly or only addressing other diseases
(e.g. classical homocystinuria) or MTHFR polymor-
phisms (e.g. C677T) or without information relevant to
the outcomes of interest (e.g. mutation reports only) by
screening of abstracts. In total, 174 publications were
included in the qualitative data analysis. The clinical
characterisation of the diseases (Table 1) was based on
117 publications.
The following main questions and outcomes of interest in
males and females with any type of onset (early or late) of one
of the diseases of interest were addressed (outcomes in
parentheses).
– Which clinical signs are characteristic and allow timely
diagnosis (Outcome: timely clinical diagnosis; this out-
come is considered important)
– Which biochemical parameters allow timely and valid
diagnosis? (Outcome: valid, timely laboratory diagnosis;
this outcome is considered important)
– How can we prevent death and avoid/treat severe organ
damage (Outcome: survival, severe organ complications;
this outcome is considered critical)
– How can we prevent or treat eye disease and
neurocognitive impairment? (Outcome: visual and
neurocognitive function; this outcome is considered
critical)
In a first step, all reports made available to the panelists
were graded according to the Scottish Intercollegiate
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Fig. 1 Remethylation disorders:
metabolic pathways. MTHFR
methylenetetrahydrofolate
reductase, THF tetrahydrofolate,
Gly glycine, Ser serine, DHF
dihydrohydrofolate, Met
methionine, Hcy homocysteine,
AdoMet adenosylmethionine,
AdoHcy adenosylhomocysteine,
MS methionine synthase, MSR
methionine synthase reductase,
BHMT betaine homocysteine
methyltransferase, CBS
cystathionine-beta-synthase,
DMG dimethylglycine, MeCbl
methylcobalamin, AdoCbl
adenosyl-Cbl
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Table 1 Signs and symptoms reported in 396 individuals. ++++Very frequently (>50% of cases); +++ frequently (25–50% of cases); ++ infrequently
(10–25 % of cases); + occasionally seen (<10 % of cases). (+) Single case reports, probably disease-related conditions
cblC cblD-MMA/HC cblF cblD-HC cblE cblG MTHFR deficiency
Number of reported cases 169 16 13 5 20 25 148
Eating disorders/failure to gain weight
Small for gestational age + ++ (+)
Feeding difficulties, failure to thrive +++ ++++ +++ +++ ++++ ++
Nervous system
Decreased consciousness +/− apnoea ++ (+) +++ +++ +++
Seizures +++ ++++ ++ (++) +++ +++ +++
Ataxia + (++) (+) ++ ++
Movement disorder and/or abnormal muscle tone +++ +++ +++ ++++ +++ ++++ +++
Peripheral neuropathy/subacute degeneration of spinal cord ++ (+) (++) ++ ++ ++
Hydrocephalus ++ ++ ++ ++
Visual impairment (retinopathy, optic atrophy) +++ ++ +++ ++ ++ +
Developmental disorder/ cognitive impairment +++ +++ ++++ ++++ ++++ ++++ ++++
Behavioural/mental disorders ++ ++ ++++ (+) ++
Microcephaly ++ ++++ ++ + ++
Blood and bone marrow
Megaloblastic anaemia ++ ++ +++ +++ ++++ ++++ +
Pancytopenia/neutropenia ++ +++ ++ +
Recurrent severe infections (+) ++
Kidneys
Haemolytic uraemic syndrome ++ ++ ++ (+)
Glomerulopathy + (+)
Tubulointerstitial nephropathy +
Cardiopulmonary
Cardiac malformation + +++
Cardiomyopathy ++
Interstitial pneumonia +
Pulmonary hypertension +
Vascular
Stroke (+) (+) +
Venous thrombosis/ embolism + (+) +
Malformations
Facial dysmorphism + (+)
Skeletal deformity (+) +
Gastrointestinal
Cheilitis/gastritis +++
Liver steatosis + ++
Skin
Dermatitis/rash/hyperpigmentation + ++ +
Other
Hydrops fetalis +
Metabolic acidosis and/or hyperammonaemia +
Temperature instability/hypothermia + (+)
Legend: The frequencies depicted in Table 1 are derived from collated case reports and may not be fully representative. However, they do not
significantly deviate from published case series (Ogier de Baulny et al 1998; Carrillo-Carrasco et al 2012; Fischer et al 2014; Huemer et al 2016).
The true prevalence of organ manifestations also depends on the extent of technical investigations, especially in relation to milder forms of microan-
giopathy and retinopathy that may escape clinical detection. Due to the very small number of reported cblJ cases, these have not been included
References: Fischer et al 2014; Al Essa et al 1999; Al Tawari et al 2002; Alfadhel et al 2011; Andersson et al 1999; Andersson and Shapira 1998; Arai and
Osaka 2011; Arn et al 1998; Atkinson et al 2014; Augoustides-Savvopoulou et al 1999; Backe et al 2013; Baumgartner et al 1979a; Baumgartner et al
1979b; Beauchamp et al 2009; Bellini et al 1992; Ben-Shachar et al 2012; Biancheri et al 2002; Biancheri et al 2001; Biotti et al 2014; Birnbaum et al
2008; Bishop et al 2008; Brandstetter et al 1990; Broomfield et al 2014; Brunel-Guitton et al 2010; Brunelli et al 2002; Cappuccio et al 2014; Carmel et al
1980; Carmel et al 1988; Carrillo-Carrasco et al 2009; Carrillo-Carrasco et al 2012a, b; Cerone et al 2000; Chang et al 2011; Clayton et al 1986; Coelho
et al 2008; Cogan et al 1980; D’Aco et al 2014; D’Alessandro et al 2010; De Bie et al 2009; Dionisi-Vici et al 2013; Ellaway et al 1998; Engelbrecht et al
1997; Enns et al 1999; Fuchs et al 2012; Geraghty et al 1992; Gerth et al 2008; Goodman et al 1970; Goyette et al 1996; Goyette et al 1995; Goyette et al
1994; Grant et al 2009; Grünert et al 2011; Guigonis et al 2005; Gulati et al 1997; Haan et al 1985; Harding et al 1997; Harpey et al 1981; Haworth et al
1993; Holme and Ronge 1989; Howard et al 1997; Huemer et al 2005, 2014, 2015a, b; Hyland et al 1988; Kanwar et al 1976; Kind et al 2002; Lesesve
and Latger-Cannard 2013; Levy et al 1970; Longo et al 2005; Lossos et al 2014; Mah et al 2013; Martinelli et al 2011; Matos et al 2013; Menni et al
2012;Michot et al 2008;Mitchell et al 1986;Morel et al 2005;Mudd and Freeman 1974; Nishimura et al 1985; Ogier de Baulny et al 1998; Pasquier et al
1994; Patton et al 2000; Paul et al 2013; Powers et al 2001; Prasad et al 2011; Profitlich et al 2009a, b; Regland et al 1994; Ribes et al 1990; Ricci et al
2005; Ronge and Kiellman 1996; Rosenblatt et al 1985; Rosenblatt et al 1986; Rossi et al 2001; Rutsch et al 2009; Schiff et al 2011; Schimel and Mets
2006; Selzer et al 2003; Shih et al 1989; Shinnar and Singer 1984; Sibani et al 2000; Smith and Bodamer 2002; Steen et al 1997; Stucki et al 2012;
Suormala et al 2004; Tanpaiboon et al 2013; Tomaske et al 2001; Tonetti et al 2003; Traboulsi et al 1992; Ucar et al 2010; Urbón Artero et al 2002;
Urreizti et al 2010; Visy et al 1991; Waggoner et al 1998; Wang et al 2014; Watkins and Rosenblatt 1989; Wu et al 2005
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Guidelines Network (SIGN) criteria by the authors who had
assigned themselves according to their expertise to five major
working groups focusing on the topics Bclinical signs and
symptoms^; Bdifferential diagnosis^; Blaboratory/biochemical
parameters^; Bdisease course and outcome^; Btreatment^. Due
to the rarity of the diseases, studies and reports of all types of
designs (from case reports and case series to metaanalyses)
were included; randomised controlled trials were not
available.
The working groups prepared drafts on their topics,
which were carefully evaluated in moderated discussion
groups. Elaboration and grading of recommendations was
accomplished by moderated, consensus-oriented discus-
sions according to the BGrading of Recommendations
Assessment, Development and Evaluation (GRADE) work-
ing group^ approach (http://www.gradeworkinggroup.org/;
Guyatt et al 2011a, b, c, 2012); a patient representative
was present at these meetings. Finally, for each outcome
the quality of the evidence was rated in one of three
categories (low, moderate, high) as defined by the GRADE
working group. The strength of a recommendation (strong
recommendation, recommendation and suggestion; for more
information see Supplementary material) was summarised
from written assessments from the panelist using the follow-
ing set of questions:
– Are you confident that the benefits outweigh the harms/
burden or vice versa?
– Is there high, moderate or low quality evidence? Please
consider:
Risk of bias
Study design
Directness and consistency of results
Magnitude of effect
Dose–response gradient
Publication bias
– Are you confident that the recommendation meets typical
values and preferences of the target population (e.g. pa-
tients, parents)?
– Are the resources worth the expected net benefit follow-
ing the recommendation?
– Overall strength of recommendation: weak or strong?
Data derived from case reports, case series or any
other type of observational studies were by principle
rated as low quality evidence. However, evidence for
some outcomes was considered moderate on the basis
of high consistency of results. High quality of evidence
was only available for betaine treatment in MTHFR de-
ficiency. This evidence was based on a metaanalysis,
which revealed direct and consistent results as well as
a relationship between time of onset of treatment and
outcome.
Which clinical signs are characteristic
for remethylation defects and allow for timely
diagnosis?
General clinical patterns of remethylation disorders
The published clinical presentations of patients suffering
from remethylation disorders (summarised in Table 1)
reveal no specific, distinct signs and symptoms but rath-
er highlight that these conditions affect multiple systems
and thus often present in a rather multifaceted manner.
Nevertheless, a few patterns of clinical presentations can
be identified.
Most prominently, the central and peripheral nervous
system and the bone marrow are affected. Developmental
and neurocognitive impairment, feeding problems, neuro-
logical symptoms including seizures, movement disorders,
abnormal muscle tone, visual impairment, neuropathy and
haematological abnormalities are present in the majority of
patients. In many patients, renal manifestations, e.g. atyp-
ical haemolytic uraemic syndrome (HUS) or glome-
rulopathy, mostly related to microangiopathy, have been
identified.
Clinical presentations may vary considerably. Severe
acute encephalopathy, macrocytic anaemia, atypical
HUS, cardiopulmonary signs, subacute combined degen-
eration of the cord or psychiatric symptoms, each iso-
lated or in combination with other symptoms may be
present. Therefore, in particular, a combination of neu-
rological and haematological symptoms, often in the
presence of failure to thrive or feeding difficulties
should raise suspicion of a remethylation disorder (see
references to Table 1).
Age specific patterns of remethylation disorders
Findings from published case reports indicate that the patterns
of clinical manifestation of remethylation disorders vary with
age (Table 2).
Clinical patterns specific for combined remethylation
disorders (cblC, cblD-MMA/HC, cblF, cblJ)
Severe intrauterine growth retardation is rare, whereas postna-
tal growth failure and feeding difficulties are very frequent.
Three quarters of children with combined disorders manifest
during the neonatal period or in early infancy. Neonates typ-
ically show lethargy, seizures and muscular hypotonia, often
in combination with megaloblastic anaemia or neutropenia/
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pancytopenia. Up to 50 % of infants exhibit signs of visual
impairment such as nystagmus on the background of retinop-
athy or optic atrophy (Bonafede et al 2015; Weisfeld-Adams
et al 2015; Brooks et al 2016). Microangiopathic renal or
pulmonary disease mostly manifests early but may also be
present in older children or adults (Grangé et al 2015;
Kömhoff et al 2013; Sharma et al 2007).
Older infants and young children often show signs of
acute encephalopathy; visual and cognitive impairment
are prevalent. Older children, adolescents and adults
may present with acute or chronic behavioural or psy-
chiatric abnormalities, cognitive impairment, signs of
peripheral neuropathy and ataxia that reflect subacute
degeneration of the spinal cord or rarely venous throm-
boembolism (Rahmandar et al 2014; Huemer et al 2014;
Grangé et al 2015). Other than optic pallor, ocular man-
ifestations are rare in late-onset cblC (Gizicki et al
2014; Weisfeld-Adams et al 2015).
Clinical patterns specific for isolated remethylation
disorders (cblD-HC, cblE, cblG)
The less prevalent isolated disorders of methionine syn-
thase generally present similar to combined disorders.
The typical clinical patterns of the cblE and the cblG
defect are indistinguishable. Affected individuals usually
manifest in infancy, mostly with haematological abnor-
malities, muscular hypotonia and neurocognitive impair-
ment. One third of all patients present with impaired
consciousness, seizures, and one quarter with signs of
visual impairment. Older children and adults can mani-
fest with signs reflecting spinal cord involvement (sub-
acute degeneration of the spinal cord) or psychiatric
symptoms (Huemer et al 2015a). Single cases with iso-
lated macrocytic anaemia without neurocognitive impair-
ment have been reported (Vilaseca et al 2003; Ruiz-
Mercado et al 2015).
Clinical patterns specific for MTHFR deficiency
MTHFR deficiency mainly presents in early childhood
but can potentially present at any age with a high prev-
alence of cognitive impairment. Neonates and young
infants often manifest with feeding difficulties, de-
creased consciousness, hydrocephalus and muscular hy-
potonia. Apnoea is a frequent complication (Broomfield
et al 2014; Diekman et al 2014; Huemer et al 2016;
Schiff et al 2011; Strauss et al 2007).
Older infants and children frequently manifest with sei-
zures and cognitive impairment, often displaying acquired
microcephaly. With increasing age, peripheral neuropathy,
gait abnormalities and spasticity may become evident and
some older patients manifest with additional or even isolated
behavioural or psychiatric disorders (Birnbaum et al 2008;
Michot et al 2008).
Individuals withMTHFR deficiency do not usually present
with haematological abnormalities. There are just a few
Table 2 Age-related clinical presentations of remethylation disorders
Neonates (0–28 days)
Encephalopathy
Lethargy, apnoea
Feeding difficulties
Muscular hypotonia
Seizures
Nystagmus
Anaemia/thrombocytopenia or pancytopenia, megaloblastosis
Haemolytic uremic syndrome
Cardiomyopathy
Hydrocephalus
Pulmonary hypertension
Infants (1–12 months)
Growth failure/poor weight gain
Acute progressive encephalopathy/apnoea
Chronic encephalopathy
Muscular hypotonia
Developmental disability/regression
Seizures
Recurrent acute behavioural changes/lethargy
Visual inattention/Nystagmus
Anaemia/thrombocytopenia or pancytopenia, megaloblastosis
Haemolytic uremic syndrome
Pulmonary hypertension
Children (1–12 years)
Chronic Encephalopathy
Muscular hypotonia or spasticity
Developmental disability/regression or dementia
Seizures
Neuropsychiatric disturbance/personality changes
Intermittent acute behavioural changes/lethargy
Acute progressive encephalopathy/apnoea
Subacute degeneration of the cord
Paraesthesia
Incontinence
Ataxia/spasticity
Progressive limb weakness (legs>arms)
Haemolytic uremic syndrome
Thromboembolic events
Recurrent venous thrombosis
Pulmonary thromboembolism
Cerebrovascular events
Pulmonary hypertension
Adolescents and adults (>12 years)
Chronic encephalopathy
Developmental disability/regression or dementia
Neuropsychiatric disturbance
Personality changes
Intermittent acute behavioural changes/lethargy
Acute progressive encephalopathy
Subacute degeneration of the spinal cord
Paraesthesia
Incontinence
Ataxia/spasticity
Progressive limb weakness (legs>arms)
Thromboembolic events
Recurrent venous thrombosis
Pulmonary thromboembolism
Cerebrovascular events
Pulmonary hypertension
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reports of older children and adults with megaloblastic anae-
mia in association with long-standing neurological manifesta-
tions (Broomfield et al 2014; Schiff et al 2011).
Outcome: timely clinical diagnosis
Recommendation 1: We strongly recommend consideration
of an acquired or genetic disorder of
remethylation in the case of neurologi-
cal and/or visual and/or haematological
symptoms. (Quality of the evidence:
moderate)
Recommendation 2: We strongly recommend considering
an acquired or genetic disorder of
remethylation in the case of unex-
plained thrombosis and/or spinal cord
degeneration and/or atypical HUS.
(Quality of the evidence: moderate)
Clinical differential diagnosis
All clinical presentations of genetic disorders of remethylation
can be mimicked by common conditions, which reduce
the availability of folate or cobalamin such as nutrition-
al deficiency, acquired malabsorption or drug-associated
effects (Table 3). Maternal vitamin B12 deficiency due
to a strict vegan diet or to undiagnosed pernicious
anaemia needs to be excluded in neonates and young
infants presenting with signs of a remethylation disor-
der or identified by newborn screening (NBS) and sub-
normal vitamin B12 concentrations (Scolamiero et al
2014).
A number of other rare genetic diseases can mimic
defects in intracellular cobalamin metabolism and
should be considered in children with clinical signs
and biochemical hallmarks of a remethylation disorder
but with normal serum concentrations of vitamin B12
and folates: transcobalamin (TC) deficiency is bio-
chemically and clinically indistinguishable from com-
bined cobalamin disorders (Trakadis et al 2014). The
recently discovered MTHFD1 deficiency (Watkins and
Rosenblatt 2012) affects folate metabolism and can
cause mild hyperhomocysteinaemia. The five patients
described so far displayed severe megaloblastic anae-
mia and pancytopenia, immunological problems and re-
nal microangiopathy (Burda et al 2015).
The HCFC1 X-linked defect (cbl X, Yu et al 2013) is
sometimes associated with disturbed function of the
CblC protein but its diagnosis can be challenging be-
cause not all affected boys have elevated homocysteine
concentrations. Clinical hallmarks are neonatal or early
infantile onset of severe developmental disorder, promi-
nent epileptic seizures, cognitive impairment and a dystonic-
choreatic movement disorder; moderately elevated MMA
was observed in all 14 patients reported by Yu et al 2013
(Table 4).
Which parameters allow valid and timely laboratory
diagnosis?
Patients with a suspected remethylation disorder require
immediate and urgent biochemical investigation (Fig. 2).
The diagnosis of remethylation disorders can be con-
firmed by investigations at the levels of metabolites,
enzymatic studies and/or molecular genetic analysis.
Biochemical metabolites
Plasma total homocysteine (tHcy) is the first biochemi-
cal parameter to assess when a remethylation disorder is
suspected. THcy levels usually are >50 but mostly
>100 μmol/L in untreated patients with remethylation
disorders (Carrillo-Carrasco et al 2009; Van Hove et al
2002; D’Aco et al 2014; Miousse et al 2009).
Table 3 Conditions that mimic intracellular disorders of remethylation
Affecting cobalamin availability
Nutritional inadequacy (maternal vitamin B12 deficiency/vegan diet)
Intestinal malabsorption (e.g. genetic disorders such as
Imerslund-Graesbeck syndrome gastric intrinsic factor deficiency; au-
toimmune or parasitic disease; short gut syndrome)
Disturbed binding and cellular uptake (e.g. TC deficiency)
Disturbance of intracellular metabolism (nitrous oxide)
Affecting folate availability
Nutritional inadequacy (maternal deficiency/dietary inadequacy)
Intestinal malabsorption (acquired/genetic)
Disturbed binding and cellular uptake of folate (autoimmune/genetic)
Disturbance of intracellular metabolism (antifolate drugs, MTHFD1
deficiency)
Other diseases with a combination of haematological and neurological
symptoms
Severe iron deficiency
Infectious diseases (e.g. CMV/EBV/HHV6/HPVB19/HIV1)
Leukaemia/myeloproliferative disorders
Myelodysplastic syndromes
Disorders affecting the mitochondrial respiratory chain (e.g. Pearson
syndrome)
UMP synthase deficiency (orotic aciduria)
Thiamine transporter (SLC19A2) defect
Branched chain organic acidaemia such as methylmalonic or propionic
acidaemia
Lysinuric protein intolerance
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Routinely, tHcy is measured by chromatographic methods
or immunoassays. Chromatographic methods are more specif-
ic than immunoassays and are usually coupled with tandem
mass spectrometry (MS/MS) detection allowing simultaneous
determination of other compounds of interest for diagnosis
and follow up of these diseases, e.g. Met, cysteine (Refsum
et al 2004) or possibly cystathionine (Stabler et al 1993;
Stabler et al 2013).
There is no influence of the type of collection tube
used (EDTA, heparinised, citrate, serum, gel separator
Table 4 Differential diagnosis of
inborn errors of metabolism
presenting with
hyperhomocysteinaemia
Macrocytosis or
macrocytic
anaemia
MMA Met Total vitamin
B12
Folate
cblC
cblD-MMA/HC
+ or − ↗ ↘↘ to nl nl nl
cblF/cblJ + ↗ ↘↘ to nl nl nl
cblE/G + nl ↘↘ to nl nl nl
cblD-HC + or − nl ↘↘ to nl nl nl
MTHFR – nl ↘↘ to nl nl nl or↘
Vitamin B12 deficiency or
malabsorption
+ ↗ ↘ to nl ↘↘ nl
Folate deficiency or malabsorption + nl ↘ to nl nl ↘↘
HCFC1 (cblX) + or − ↗ or nl ↘↘ to nl nl nl
CBS deficiency – nl nl-↗ nl nl
TC deficiency + ↗ ↘↘ to nl nl (↘) nl
MTHFD1 deficiency* + nl ↘↘ to nl nl nl
*Hyperhomocysteinaemia present in some patients, normal (nl) tHcy levels in others
Clinical presentation compatible with
remethylation disorder
Obtain complete diagnostic sample set: 
serum VitB12 and folate; plasma tHcy and methionine (Met);  
acylcarnitine pattern, plasma or urinary methylmalonate (MMA) 
Start parenteral hydroxocobalamin (OHCbl) (1 mg/d)
Plasma tHcy elevated; plasma Met normal or decreased
Seek expert advice!
Continue parenteral OHCbl
Consider oral betaine, folinic acid/methylfolinate, L-methionine
VitB12N, Folate N,
tHcyN, MMAN
No remethylation 
defect
VitB12 , Folate N, 
tHcy - , MMA
Perturbation of VitB12  
supply/transport 
VitB12N, Folate , 
tHcy , MMA N
Perturbation of folate 
supply/transport
VitB12N, Folate N, 
tHcy - , MMA N
cblD-HC,
cblE, cblG 
VitB12N, Folate N, 
tHcy - , MMA
CblC,cblD-MMA/HC, cblF,
cblJ or TC deficiency 
Continue parenteral OHCbl; 
Continue/start oral betaine
Continue/consider
L-methionine and/or 
folinic acid/methylfolate 
supplementation
Positive Neonatal Screening
Initiat further diagnostic steps
Supplement VitB12/folate as required 
Stop parenteral OHCbl
Continue/start oral betaine
Continue/consider 
folinic acid/methylfolate 
and/or L-methionine
supplementation
MTHFR 
deficiency
Initiate further diagnostic steps
Consider MTHFD1 deficiency
Stop parenteral OHCbl treatment
Elevated plasma total homocysteine
(tHcy)
Fig. 2 Diagnostic pathway and management of the patient with a suspected remethylation disorder. All biochemical results refer to pre-treatment
samples. N=normal
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tubes). However, blood samples should be centrifuged
within 1 h or kept cold until centrifugation (<6 h).
After removal of blood cells, tHcy is stable for several
weeks at 4 °C and for several years after freezing
(Refsum et al 2004).
Free homocystine in plasma or urine measured by conven-
tional ion-exchange chromatography is not the method of
choice since it may remain undetectable even in the presence
of significantly elevated tHcy in plasma (Fowler and Jakobs
1998; Moat et al 1999).
To further discriminate remethylation disorders from
other hyperhomocysteinaemias, determination of urinary
(or plasma) MMA (Fowler and Jakobs 1998), plasma
Met, blood acylcarnitine profile, serum vitamin B12
and folate are required and should promptly be deter-
mined (see Figs. 1 and 2). In case shipment of urine or
blood samples is difficult, an experienced laboratory
should give advice on the investigation of the parame-
ters from DBS. Treatment should not be delayed by
waiting for confirmation of the exact defect.
Outcome: valid, timely laboratory diagnosis
Recommendation 3 & Elevated plasma tHcy is the hall-
mark of remethylation disorders.
We strongly recommend that in-
vestigations in patients with a
suspected remethylation disorder
should start with the measurement
of total homocysteine in blood. We
recommend the blood sample for
tHcy to be centrifuged within an
hour and kept at +4° or frozen until
analysis. Immunoassays or chro-
matographic methods are suitable
for tHcy measurement. (Quality of
the evidence: moderate)
Recommendation 4 & We strongly recommend against
measuring free homocysteine in-
stead of total homocysteine. (Qua-
lity of the evidence: moderate)
Recommendation 5 & We strongly recommend that in the
case of high total homocysteine,
plasma and urine samples for de-
termination of MMA, methionine,
folate and vitamin B12 are to be
obtained before treatment is
started. (Quality of the evidence:
moderate)
Differential diagnosis of biochemical parameters
Hyperhomocysteinaemia is the hallmark of the remethylation
and transulfuration disorders. Mild to moderate hyperhomo-
cysteinaemia is common in vitamin B12 or folate deficiencies
but also in very severe vitamin B6 deficiency and in patients
with renal failure or hypothyroidism. While megaloblastic
anaemia with increased MCV and hypersegmented neutro-
phils on blood film are found in both vitamin B12 and folate
deficiencies, elevated MMA is only observed in functional
vitamin B12 deficiency (Whitehead 2006).
In the case of normal serum vitamin B12 and folate levels,
TC deficiency, primary remethylation and transulfuration disor-
ders should be considered. Holotranscobalamin measurement,
which unfortunately is performed only in a few laboratories
shows low levels in TC deficiency; this disorder can be con-
firmed bymolecular genetics investigation (Trakadis et al 2014).
The plasma Met concentration differentiates between
remethylation disorders and deficiency of CBS, a key enzyme
of the transulfuration pathway. Methionine is low or normal in
remethylation disorders while it is usually elevated or at least
borderline normal in CBS deficiency (Mudd 2011).
Megaloblastic anaemia with increased MCV is often ob-
served in the neonatal forms of intracellular cobalamin defects
(cblF, cblJ, cblC, cblD-MMA/HC, cblD-HC, cblE and cblG)
but less frequently in the late onset forms of these disorders
and not normally in MTHFR deficiency (Rosenblatt et al
1997; Carrillo-Carrasco et al. 2013).
The recently described HCFC1 defect (cbl X) has a different
pathophysiological background and is beyond the scope of these
guidelines. All 14 patients presented with moderately increased
MMA and five of these patients had hyperhomocysteinaemia
(Yu et al 2013). In two of the five published patients with meth-
ylenetetrahydrofolate dehydrogenase 1 deficiency, tHcy concen-
trations were moderately elevated (Burda et al 2015) (Table 4).
Enzymatic studies
Direct enzyme assays are only available for MTHFR, methio-
nine synthase and methionine synthase reductase (Suormala
et al 2002; Gulati et al 1997; Olteanu and Banerjee 2001).
These direct enzyme assays can be problematic.MTHFR should
be assayed in cultured skin fibroblasts preferably in the physio-
logical direction of the reaction (Suormala et al 2002). Apo-
methionine synthase and holo-methionine synthase (methionine
synthase plus methionine synthase reductase) activities can be
measured by the same reaction but with different conditions of
reduction (Yamada et al 2006).
Indirect assays measuring the integrity of several enzymes
in the same pathway are useful for remethylation disorders
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investigations. Incorporation of 1-[14C]-propionate into amino
acids and then cell proteins via the propionate pathway reflects
the level of intracellular synthesis of adenosylcobalamin.
Incorporation of [14C]-methyltetrahydrofolate intomethionine
explores the methionine synthase and methionine synthase
reductase activities and the capacity of the cells to produce
methylcobalamin. Incorporation of [14C]-formate into methi-
onine or serine reflects the activities of the methylene-
tetrahydrofolate dehydrogenase, methylene-tetrahydrofolate
reductase and the methionine synthase/methionine synthase
reductase activities (Table 5). These tests also allow the as-
sessment of possible in vitro vitamin-responsiveness of the
relevant disorders (Suormala et al 2002; Gulati et al 1997;
Olteanu and Banerjee 2001). Enzyme assays are needed to
characterise functional consequences of new variants identi-
fied by molecular genetic investigations including next gener-
ation sequencing.
Molecular genetic analysis
The cblC gene (MMACHCOMIM 609831) is located in chro-
mosome region 1p34.1 and has five exons (Lerner-Ellis et al
2006). The three most common mutations c.271dupA,
c.394C>T and c.331C>T have been identified in the
MMACHC gene. The c.271dupA that represents about 30 %
of the identified alleles and c.331C>T mutations are associat-
ed with early onset disease. The c.394C>T mutation is asso-
ciated mainly with late onset disease. The c.609G>Amutation
accounts for 85 % of the identified alleles in Chinese patients,
and even though it leads to a premature termination codon it
remains predominantly associated with late onset disease in
this population (Wang et al 2010) but has been observed in
some early-onset cases in other populations (Weisfeld-Adams
et al 2013). Other mutations have been shown to cluster ac-
cording to ethnicity (Morel et al 2006; Nogueira et al 2008).
The precise function of MMACHC is not completely un-
derstood. Recombinant MMACHC binds cobalamin, can
function in vitro as a cyanocobalamin (CNCbl) decyanase
(Kim et al 2008) and can dealkylate other cobalamin forms
(Hannibal et al 2009). MMACHC may act as an intracellular
cobalamin trafficking chaperone that carries out targeted de-
livery of cobalamin to and from other cobalamin-related pro-
teins (Lerner-Ellis et al 2009).
In contrast to the cblC defect which presents exclusively as
combined hyperhomocysteinaemia with MMA-uria, cblD pa-
tients can have three distinct biochemical phenotypes: isolated
hyperhomocysteinemia (cblD-HC), isolated MMA-uria
(cblD-MMA, beyond the scope of these guidelines), or com-
bined hyperhomocysteinemia and MMA-uria (cblD-MMA/
HC). MMADHC (OMIM 611935) is the gene responsible for
cblD defect (Suormala et al 2004; Coelho et al 2008).
Genotype–phenotype correlation analysis of the three cblD
variants suggests that the N- and C-terminal regions of
MMADHC have specific effects on functions in the mitochon-
drion and cytoplasm, respectively (Stucki et al 2012; Miousse
et al 2009). cblD-HC retains mitochondrial function with a
Table 5 Representation of the cobalamin defects associated with hyperhomocysteinaemia, the respective enzymatic/incorporations tests available and
the genes involved in these diseases
cblC cblD-MMA/HC cblF cblJ cblD-HC cblE cblG MTHFR
Direct enzyme assay
(tissues)
no no no no no yes yes yes
fib/leuc/amn fib/leuc/amn fib/leuc/amn
Indirect enzyme assays
Propionate incorporation ↘ ↘ ↘ ↘ nl nl nl nl
MTHF incorporation ↘ ↘ ↘ ↘ ↘ ↘ ↘ nl
Formate incorporation
into serine
↘ ↘ ↘ ↘ ↘ ↘ ↘ nl or ↗
Formate incorporation
into methionine
↘ ↘ ↘ ↘ ↘ ↘ ↘ ↘
AdoCbl biosynthesis ↘ ↘ ↘ ↘ nl nl nl nl
MeCbl biosynthesis ↘ ↘ ↘ ↘ ↘ ↘ ↘ ↘
Gene MMACHC1 MMADHC2 LMBRD13 ABCD44 MMADHC2 MTRR5 MTR6 MTHFR7
Chromosome location 1p34.1 2q23.2 6q13 14q24.3 2q23.2 5p15.31 1q43 1p36.22
Mode of inheritance AR AR AR AR AR AR AR AR
OMIM 609831 611935 612625 603214 611935 602568 156570 607093
fib fibroblasts, leuc leukocytes, amn amniocytes, AR autosomal recessive, nl normal
1 Lerner-Ellis et al 2006; 2 Coelho et al 2008; 3 Rutsch et al 2009; 4 Coelho et al 2012; 5 Leclerc et al 1998; 6 Li et al 1996; 7 Goyette et al 1994, 1995
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full-length protein which harbours only C-terminal missense
mutations in conserved residues; cblD-MMA retains cytoplas-
mic function due to translation of an error-free C-terminus
facilitated by downstream re-initiation; and in cblD-MMA/
HC complete loss of functionality occurs with deleterious mu-
tations that are localised downstream of Met116 (Jusufi et al
2014).
To date, there have been no obvious genotype-phenotype
correlations in cblF (LMBRD1, OMIM 612625) (Armour et al
2013), cblJ (ABCD4, OMIM 603214) (Coelho et al 2012),
cblE (MTRR, OMIM 602568) and cblG (MTR, OMIM
156570) (Watkins and Rosenblatt 1989; Huemer et al 2015a).
If clinical and biochemical parameters are characteristic for
a combined remethylation disorder it may be—dependent on
the population—a pragmatic approach to look first for cblC,
the most frequent remethylation disorder by searching for the
common mutation (c.271dupA) or MMACHC sequencing. If
these analyses however prove negative, functional and/or
complementation studies in fibroblasts or extended molecular
genetic testing for other defects are needed.
For MTHFR deficiency (OMIM 6070993) the majority of
mutations are private and neither type nor location of mutation
correlates with clinical phenotype (Froese et al 2016). Genetic
testing for MTFHR deficiency should be interpreted with cau-
tion since there are numerous polymorphisms in this gene,
which have been related to various common disorders and
conditions. Polymorphisms in general including the most in-
vestigated thermolabile variant c.677C>T in MTHFR are not
responsible for severe remethylation disorders (Tsang et al
2015).
Outcome: valid, timely laboratory diagnosis
Recommendation 6 & We strongly recommend diagnostic
confirmation by molecular genetic
analysis and/or direct or indirect en-
zyme assays in cultured skin fibro-
blasts (or lymphocytes) in experi-
enced laboratories. (Quality of the
evidence: moderate)
Prenatal diagnosis
Metabolites concentration (tHcy and MMA) in cell-free
amniotic fluid, enzyme activity of MTHFR and methio-
nine synthase or methionine synthase reductase in cul-
tured amniotic cells and incorporation of propionate and
methyltetrahydrofolate have been used for many years
(Fowler and Jakobs 1998; Merinero et al 1998) and
their combined use is reliable (Morel et al 2005).
Indirect enzyme assays in chorion biopsy should be
avoided (Morel et al 2005; Merinero et al 1998).
However nowadays, the molecular genetic diagnosis is the
most advisable method provided the causal mutations in the
index case and carrier status in the parents have been identi-
fied. Molecular genetic testing can be performed from chori-
onic villi or amniotic fluid samples (Morel et al 2005).
Outcome: valid, timely laboratory diagnosis
Recommendation 7 & If prenatal diagnosis is considered in
individual cases we recommend to
perform molecular genetic analysis
from chorionic villi or amniotic fluid
samples given that mutations in the
index case and carrier status in the
parents have been identified (Quality
of the evidence: low)
Feasibility and impact on outcome of newborn screening
(NBS) for combined remethylation disorders
NBS for the cblC defect should be considered since survival
and prevention of severe complications such as HUS, hydro-
cephalus and haematological abnormalities in early-onset pa-
tients can be improved by early treatment (Huemer et al
2015b). The impact of early treatment on neurocognitive de-
velopment is unclear and early treatment has little influence on
eye disease (Weisfeld-Adams et al 2013). In most late-onset
cblC patients, dementia, renal function, myelopathy and axo-
nal neuropathy improve on treatment and long-lasting disease
existing before treatment initiation correlates with residual
pathologies (Huemer et al 2014). There is insufficient data
on NBS for other combined remethylation disorders.
Outcome: survival, severe organ complications; visual and
neurocognitive function
Recommendation 8 & We strongly recommend early treat-
ment in patients with the cblC defect
as it improves survival, corrects hae-
matological abnormalities and may
prevent HUS and hydrocephalus.
However, early treatment has little
influence on eye disease and unclear
impact on neurocognitive outcome
(Quality of the evidence: moderate)
Present knowledge allows no conclusion concerning the
clinical benefit of early treatment for the cblD-MMA/HC,
cblF and cblJ defects.
The Region 4 Stork (R4S) data indicate that the sen-
sitivity of C3/C2 as primary markers is superior to Met
and Met/Phe (McHugh et al 2011). However, specificity
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of C3 and/or C3/C2 for detecting these diseases is gen-
erally low (la Marca et al 2007; Tortorelli et al 2010).
The positive predictive value substantially increased
from 4 to 100 % by measurement of MMA and 11 to
36 % by measuring tHcy as second tier analytes in DBS
(la Marca et al 2007; Tortorelli et al 2010). The sensi-
tivity of C3 and C3/C2 for mild/late-onset forms is un-
known. It is of note that neonatal metabolic distur-
bances due to maternal vitamin B12 deficiency may
also be detected. It has recently been shown that
heptadecanoyl-carnitine (C17) may have an even higher
predictive value for perturbations of MMA metabolism
including combined remethylation defects and may thus
be a promising first tier analyte (Malvagia et al 2015).
Outcome: timely and valid laboratory diagnosis
Recommendation 9 & We strongly recommend to obtain
plasma for determination of serum
vitamin B12 before treatment is
started in cases identified by NBS
as part of studies to exclude mater-
nal vitamin B12 deficiency. (Quality
of the evidence: moderate)
Recommendation 10 & We recommend use of C3 acylcar-
nitine and the C3/C2 ratio as primary
markers to screen for early onset
cblC defect. (Quality of the evi-
dence: moderate)
Recommendation 11 & We suggest consideration of C17
acylcarnitine as a promising prima-
ry marker to screen for early onset
cblC defect. (Quality of the evi-
dence: low)
Recommendation 12 & We strongly recommend performing
second tier testing using tHcy and
MMA to improve specificity and to
differentiate the defects from other
disorders. (Quality of the evidence:
moderate)
Feasibility and impact on outcome of NBS for isolated
remethylation disorders and MTHFR deficiency
The use of NBS for de tec t ion of the i so la ted
remethylation disorders and the MTHFR defect appears
worthy of consideration. In the cblE and cblG defect,
macrocytic anaemia (Vilaseca et al 2003; Kvittingen
et al 1997) and neurocognitive performance (Harding
et al 1997; Rosenblatt et al 1985; Schiff et al 2011;
Kvittingen et al 1997; Müller et al 2007) often respond
to treatment (Müller et al 2007; Schiff et al 2011). Eye
disease seems not to be responsive (Huemer et al 2014).
Early detection by NBS and timely treatment improved
short-term outcomes of two asymptomatic patients with
the cblE and cblG defect and three symptomatic patients
with MTHFR deficiency (Wong et al 2016). Moreover,
early betaine treatment has a clear positive impact on out-
come in MTHFR deficiency (Diekman et al 2014).
Neonatal screening for cblD-HC, cblE and cblG and
for MTHFR deficiency appears to be feasible by detecting
decreased methionine and methionine-to-phenylalanine
ratio (Bowron et al 2005) in DBS. The second-tier marker
tHcy clearly differentiates patients from controls
(McHugh et al 2011; Tortorelli et al 2010). However, suf-
ficient data on efficacy of NBS programs for these disor-
ders is lacking.
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 13 & We strongly recommend early
identification and treatment with
betaine for MTHFR deficiency.
Presymptomatic betaine treat-
ment prevents severe neurologi-
cal impairment (Quality of the
evidence: high)
Disease course and outcome of combined remethylation
disorders
Most information on complications and outcome is
based on data from patients with cblC disease. There
is limited data about the natural history of the other
combined disorders (Table 6).
Patients with the cblC defect usually present with severe
complications and historically have a poor long-term outcome
(Rosenblatt et al 1997; Andersson et al 1999; Fischer et al
2014). It is well recognised that despite treatment and im-
proved metabolic parameters, severe complications such as
developmental delay and progressive visual loss may still de-
velop (Andersson et al 1999; Enns et al 1999; Patton et al
2000; Fischer et al 2014; Weisfeld-Adams et al 2015). Even
if the neurologic status stabilises or improves with therapy, the
sequelae remain in a large proportion of patients (Whitehead
2006; Watkins and Rosenblatt 1989), especially if the initia-
tion of treatment was delayed or insufficient (Huemer et al
2014). Haematological symptoms and failure to thrive gener-
ally resolve with treatment (Martinelli et al 2011; Fischer et al
2014).
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The late-onset phenotype has a more favourable outcome
than early-onset cblC disease but is still associated with resid-
ual sequelae such as learning difficulties, neurobehavioural
symptoms, neurogenic bladder and gait abnormalities
(Rosenblatt et al 1997) and at least one patient, in whom
treatment was ceased, deteriorated and died (Thauvin-
Robinet et al 2008).
Mortality
Early detection and treatment with parenteral OHCbl appear to
have decreased the mortality in newborns with cblC. A retro-
spective analysis of 50 patients (44 presented in the first year of
life) with cblC disease reported an overall mortality rate of
30 % (Rosenblatt et al 1997). Of the 13 patients that died, four
were not treated, two received only cyanocobalamin (CNCbl),
and three were initially treated with CNCbl and then switched
to OHCbl (Rosenblatt et al 1997; Carrillo-Carrasco et al 2012).
Later, in the Fischer study about outcome in a series of 88
patients with the cblC defect, the mortality was 11.4 % (90 %
of them with infantile onset). Treatment following various
regimes of parenteral OHCbl complemented in some cases
by betaine, folate/folinic acid and carnitine resulted in im-
provement of biochemical abnormalities, non-neurological
signs and mortality (Fischer et al 2014). It has been suggested
that daily treatment with parenteral OH-Cbl combined with
betaine would be associated with a favourable outcome
(Carrillo-Carrasco et al 2012).
Renal disease and microangiopathy
Thrombotic microangiopathy (TMA) leading to atypical HUS is
the most common renal manifestation in cblC; it has also been
observed in cblD-MMA/HC patients. HUS may cause hyper-
tension, intravascular haemolysis, microscopic haematuria, pro-
teinuria and renal function deterioration, occasionally proceed-
ing to renal failure (Van Hove et al 2002; Guigonis et al 2005;
Sharma et al 2007; Geraghty et al 1992; Morath et al 2013). A
case of focal segmental glomerulosclerosis and atypical glo-
merulopathy (Brunelli et al 2002) has been reported.
Histological findings of the kidneys include widening of
the mesangium, swelling of endothelial cells with
Table 6 Main complications
according to system in
remethylation disorders
Growth and physical
features
Prenatal growth retardation and postnatal failure to thrive
Dysmorphic facial features
CNS Microcephaly
Hydrocephalus
Developmental delay and/or regression; cognitive impairment ranging from executive
dysfunction to severe mental retardation
Neuropsychiatric disturbances, social withdrawal, personality changes, dementia
Progressive encephalopathy
Seizures
Subacute combined degeneration of the spinal cord
Peripheral neuropathy
Leukoencephalopathy
Cortical atrophy
Eye Nystagmus
Maculopathy
Progressive pigmentary retinopathy
Optic atrophy
Visual impairment/blindness
Blood (Macrocytic) anaemia
Thrombocytopenia and/or neutropenia
Vascular Stroke
Recurrent venous thrombosis
Cor pulmonale or subclinical pulmonary thrombosis
Renal Haemolytic-uremic syndrome
Glomerulopathy
Heart Congenital heart defects
Left ventricular non-compaction
Dilated cardiomyopathy
Pulmonary hypertension
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detachment from the basement membrane, and granular
deposits in the subendothelial space (Van Hove et al
2002; Russo et al 1992; Brunelli et al 2002; McCully
1969). Isolated pulmonary hypertension has been ob-
served (Iodice et al 2013; Gündüz et al 2014) in cblC
patients. Early onset combined pulmonary hypertension
and renal thrombotic microangiopathy with a fatal course
in several untreated cases has been reported (Kömhoff
et al 2013), this picture is also seen in rare cases of late
onset cblC patients (Grangé et al 2015). Timely treatment
can improve outcome significantly (Grangé et al 2015;
Kömhoff et al 2013; Gündüz et al 2014).
Outcome: survival, severe organ complications
Recommendation 14 & We recommend monitoring for all
aspects of renal disease including ar-
terial blood pressure in patients with
cobalamin related remethylation dis-
orders. (Quality of the evidence:
low)
Vascular problems
Thromboembolic complications are an important cause
for morbidity and mortality in patients with cblC disease
(Martinelli et al 2011; Thauvin-Robinet et al 2008). These
include recurrent venous thrombosis (Thauvin-Robinet
et al 2008; Roze et al 2003; Augoustides-Savvopoulou
et al 1999; Bodamer et al 2001; Powers et al 2001;
Guigonis et al 2005), pulmonary thrombosis (Powers
et al 2001; Thauvin-Robinet et al 2008; McCully 1969;
Baumgartner et al 1979a, b; Van Hove et al 2002), cor
pulmonale (Profitlich et al 2009a, b) and cerebrovascular
complications (Brunelli et al 2002; Geraghty et al 1992).
tHcy levels above 45 μmol/L have been reported to be
associated with the development of vascular complica-
tions in several patients (Carrillo-Carrasco et al 2009).
Remarkably, the original case of cblC disease presenting
diffuse vascular lesions with proliferative fibrous intimal
plaques and focal necrosis of the artery wall contributed
to the development of the homocysteine theory of arterio-
sclerosis (McCully 1992).
With appropriate treatment, the incidence of thromboem-
bolic complications can be reduced and may even be
prevented in late onset patients (Huemer et al 2014).
Outcome: survival, severe organ complications
Recommendation 15 & The incidence of vascular
complications is significant-
ly reduced with appropriate
treatment in late onset pa-
tients and may be prevented
in early onset patients with
remethylation disorders.
(Quality of the evidence:
moderate)
Neurocognitive and psychiatric problems
Neurodevelopmental impairment of varying degrees is com-
mon in combined remethylation defects. Patients with early-
onset cblC disease present with a wide range of neurological
manifestations that include microcephaly, hydrocephalus, hy-
potonia, cognitive defects and seizures. Cognitive defects can
be variable, are related to disease severity and treatment onset
but may also continue to worsen despite treatment. Two treat-
ed patients with early-onset cblC disease were longitudinally
followed using neuropsychological testing. These tests
showed a decline in attention and executive functions, while
other skills were relatively spared (Beauchamp et al 2009).
Developmental delay with impairment of verbal and non-
verbal cognitive skills was also documented at follow-up of
cblF patients despite treatment (Alfadhel et al 2011; Gailus
et al 2010), but in some early treated patients, neurocognitive
outcome was satisfactory (Miousse et al 2011; Armour et al
2013). Information on outcome in the cblJ defect (Coelho et al
2012) is extremely limited; two reported patients responded
well to methylcobalamin (Kim et al 2012). In the cblD-MMA/
HC defect, some survivors showed improvement or even nor-
malisation of neurocognitive function (Suormala et al 2004;
Miousse et al 2009).
Patients with late-onset disease can show progressive en-
cephalopathy with regression, deterioration in school or work
performance, behavioural and personality changes possibly
resulting in dementia, psychosis, episodes of acute mental
confusion, lethargy and seizures that improve under specific
treatment (Huemer et al 2014).
Epilepsy is a common but nonspecific occurrence in pa-
tients with remethylation disorders. The EEG and seizure pat-
terns are nonspecific. Severely affected patients may be diffi-
cult to treat and may have recurrent status epilepticus
(Biancheri et al 2002).
Brain MRI abnormalities are common in remethylation
defects and include diffuse cerebral atrophy, white matter
changes, basal ganglia lesions and hydrocephalus.
The most common imaging findings in the early-onset
cblC cases are variable degrees of white matter abnormality
with T2 hyperintensity in periatrial and periventricular white
matter, with thinning of the corpus callosum. Basal ganglia
lesions and hydrocephalus have also been described, and may
be attributable to microvascular abnormalities (Greitz 2007).
In one cohort of young early-onset cblC patients, there was a
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high incidence of craniocaudal shortening of the pons on sag-
ittal MR images (Weisfeld-Adams et al 2013).
Cerebral atrophy and deep white matter bulk loss, which is
more pronounced posteriorly, were significant findings in late-
onset cblC disease patients (Ogier de Baulny et al 1998;
Longo et al 2005; Rossi et al 2001; Wang et al 2012).
Bilateral abnormalities of the cerebellar cortex were found in
one patient (Wang et al 2012).
The pathophysiological mechanisms underlying the white
matter abnormalities detected by MR imaging have been as-
sociated with oedema and abnormal myelination. Myelination
is closely related to methylation capacity whereby deficiency
of SAM in the CSF was shown to be associated with impaired
myelinisation (Rossi et al 2001). Moreover, a decrease in N-
acetyl aspartate (NAA) and increased lactate in the basal gan-
glia or in the periventricular white matter has been observed
on brain MR spectroscopy (Longo et al 2005; Wang et al
2012).
Spongiform white matter degeneration and demyelination
of the dorsal and lateral columns of the cord or subacute com-
bined degeneration of the spinal cord (SACD) are known com-
plications in remethylation disorders (Huemer et al 2014; Liu
et al 2015). Changes are similar to classical adult spinal cord
degeneration due to, e.g. severe nutritional vitamin B12 defi-
ciency (Scalabrino et al 2007; Maamar et al 2008). Subacute
combined degeneration of the spinal cord may be the present-
ing symptom in late onset patients or the consequence of in-
sufficient treatment. Symptoms are progressive and include
numbness of lower extremities, gait disturbances, inconti-
nence, progressive leg weakness with spastic paraparesis and
tetraplegia (Mitchell et al 1986; Ben-Omran et al 2007;
Thauvin-Robinet et al 2008; Augoustides-Savvopoulou et al
1999; Powers et al 2001; Roze et al 2003; Tsai et al 2007;
Bodamer et al 2001; Shinnar and Singer 1984).
Behavioural problems are frequent in patients with early-
onset remethylation disorders. Psychiatric manifestations
may be the presenting sign in patients with late-onset
remethylation disorders. Dementia, behavioural problems
and psychiatric symptoms have frequently been observed
in the combined (Roze et al 2003; Liu et al 2015; Huemer
et al 2014) as well in isolated remethylation disorders
(Huemer et al 2015a) and MTHFR deficiency (Birnbaum
et al 2008). In early onset cases, behavioural problems and
psychiatric symptoms can evolve over time despite treatment
(Fischer et al 2014). Late-onset cases may present with rath-
er non-specific psychiatric and behavioural symptoms,
which respond well to timely treatment (Ben-Omran et al
2007).
Ophthalmological problems
Visual dysfunction is very frequent in patients with early onset
remethylation disorders and can be rapidly progressive while
late-onset patients rarely exhibit eye disease. Current treat-
ment does not seem to modify the progression of visual dis-
ease significantly.
Maculopathy, progressive retinal dysfunction, visual im-
pairment, nystagmus, strabismus (Ricci et al 2005; Schimel
and Mets 2006; Gerth et al 2008; Weisfeld-Adams et al 2015)
and less frequently optic atrophy (Patton et al 2000; Weisfeld-
Adams et al 2015) are seen in most patients with early onset
cblC disease. Although rod cell sensitivity was reported to
improve in a patient with cblC disease following normalisa-
tion of plasma Met levels (Tsina et al 2005) generally retinal
dysfunction can be progressive and even lead to blindness
despite treatment and stabilised systemic function (Fischer
et al 2014).
The first signs of eye disease are frequently noted sev-
eral weeks after birth and include Bwandering eye
movements,^ inability to fixate and nystagmus. The fundo-
scopic exam can reveal the salt-and-pepper pigmentary
macular changes that progresses to the characteristic Bbull’s
eye^ maculopathy characterised by a hypopigmented
perimacular zone surrounded by a hyperpigmented ring or
coloboma like lesions (Robb et al 1984; Grant et al 2009;
Weisfeld-Adams et al 2015). Retinopathy can be revealed
by the electroretinogram well before clinical signs are ap-
parent (Ogier de Baulny et al 1998; Weisfeld-Adams et al
2015) showing a progressive decline in scotopic (cones)
and/or photopic (rods) responses (Schimel and Mets 2006;
Robb et al 1984; Gerth et al 2008; Gaillard et al 2008;
Weisfeld-Adams et al 2015).
Ocular coherence tomography, electroretinogram and
visual evoked potentials, are extremely useful diagnostic
and monitoring tools (Weisfeld-Adams et al 2015).
Knowledge and awareness of visual dysfunction, partic-
ularly in children with early-onset disease, allows initi-
ation of appropriate early vision intervention programs
and support (Gerth et al 2008).
Late onset patients rarely have severe visual disease (Fuchs
et al 2012; Fischer et al 2014; Gerth et al 2008). Minimal
pigmentary retinal abnormalities have been observed in some
cases (Gerth et al 2008; Weisfeld-Adams et al 2015) and the
classical Bbull’s eye^ picture has only been described in one
late-onset patient (Collison et al 2015).
Outcome: visual and neurocognitive function
Recommendation 16 & As knowledge and awareness
of visual dysfunction progres-
sion allows timely initiation of
appropriate vision interven-
tion programs and support,
we recommend that every pa-
tient newly diagnosed with a
remethylation disorder should
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receive an ophthalmological
consultation independent of
the age at diagnosis and sever-
ity of disease. (Quality of the
evidence: low)
Disease course and outcome in isolated
remethylation disorders (cblD-HC, cblE, cblG)
Disease course and outcome in isolated remethylation disor-
ders generally share many features with the combined
disorders.
Mortality
Deceased patients have been reported in the literature but the
database is too small to make a more general statement on
mortality.
Renal disease, microangiopathy and anaemia
Atypical HUS and glomerulopathy have been reported
in single patients (Paul et al 2013; Huemer et al 2015a).
Macrocytic anaemia in isolated remethylation defects
often responds to treatment (Harding et al 1997;
Vilaseca et al 2003).
Vascular problems
Thromboembolism may lead to severe clinical pathology but
has only rarely been reported (Huemer et al 2015a).
Neurocognitive and psychiatric problems
Muscular hypotonia, seizures, cognitive impairment, be-
havioural problems, psychiatric symptoms, feeding prob-
lems (Watkins and Rosenblatt 1989; Huemer et al
2015a) as well as microcephaly, brain atrophy and white
matter changes (Zavadáková et al 2005) are characteris-
tic findings during the disease course (Watkins and
Rosenblatt 1989). Hydrocephalus has rarely been report-
ed (Huemer et al 2015a).
Ophthalmological problems
Eye disease, mainly comprising retinopathy, nystagmus and
strabismus is frequently observed and seems not to respond
well to treatment (Watkins and Rosenblatt 1989; Huemer et al
2015a).
Disease course and outcome in MTHFR deficiency
Mortality
Recent experience suggests that betaine treatment if initiated
early reduces mortality in patients with MTHFR deficiency
(Diekman et al 2014)
Vascular problems
Arterial and venous thrombosis are generally rare and pre-
dominantly encountered in adolescent or adult patients (Visy
et al 1991; Tonetti et al 2002).
Neurocognitive problems
Severe neurological signs with some age-related variations
characterise MTHFR deficiency. Neurological symptoms in
MTHFR range from seizures, lethargy, apnoea and coma in
early infancy to gait disturbances with lower limb spasticity,
weakness, psychiatric behaviour such as schizophrenia-like
psychosis (Mudd and Freeman 1974; Regland et al 1994;
Pasquier et al 1994), and visual problems in adolescence/
adulthood (Haworth et al 1993; Birnbaum et al 2008).
Neonates and young infants exhibit acute neurological deteri-
oration, which may be fatal or leave severe neurological def-
icits. Older individuals typically exhibit progressive triphasic
deterioration: an initial period of normal development, then a
second phase with acquired microcephaly and psychomotor
delay, followed by abrupt deterioration associated with respi-
ratory failure that may be fatal.
In early onset severe forms clinical sequelae associated
with MTHFR deficiency include microcephaly, hydrocepha-
lus, seizures, hypotonia and global development delay, where-
as in the adolescence onset form mental retardation and pro-
gressive encephalopathy are present (Arn et al 1998; Bishop
et al 2008; Schiff et al 2011).
Some patients develop leukoencephalopathy and low-
er limb-dominant demyelinating polyneuropathy (Walk
et al 1994) and may have subacute degeneration of the
spinal cord (Hyland et al 1988). The peripheral neurop-
athy has been related to the low level of serum folic
acid (Nishimura et al 1985). Seizures are variable in
type and include myoclonic, clonic and/or tonic epi-
sodes. Infantile spasms have been described (Prasad
et al 2011). Cerebral atrophy and white matter changes
are common (Arn et al 1998; Birnbaum et al 2008).
Early treated patients exhibit a more favourable outcome
(Schiff et al 2011; Diekman et al 2014).
In MTHFR deficiency, early diagnosis and treatment are
usually associated with better neurological outcome.
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The effects of treatment on clinical outcome
Impact of prenatal treatment on outcome
Prenatal maternal treatment with parenteral OHCbl has anec-
dotally been used. For cblC disease, Trefz et al (2016) report a
favourable outcome of a pregnancy with an affected fetus
(sibling to a severely affected child) after treatment of the
mother with high-dose OHCbl (30 mg/week) and 5 mg/day
folic acid from week 15 of pregnancy. Prenatal treatment with
lower OHCbl doses resulted in biochemical improvement.
Organ complications such as microangiopathy as present in
the patient’s sibling were not observed but the patient devel-
oped eye disease and neurocognitive impairment (Huemer
et al 2005). There is no evidence regarding prenatal treatment
for the other diseases.
Outcome: survival, severe organ damage
Recommendation 17 & We suggest that prenatal mater-
nal treatment may be consid-
ered in a pregnancywith a fetus
with proven cblC disease.
(Quality of the evidence: low)
Improving the outcome in the acutely ill patient
with a suspected or proven remethylation disorder
Remethylation disorders generally present as chronic, slowly
progressive neurological disease but may also present with acute
deterioration on the background of chronic disease or with new-
onset life-threatening complications. Individuals of all ages may
manifest with a sudden thromboembolic event, microangiopath-
ic kidney or pulmonary disease, cardiomyopathy, loss of ambu-
lation or more commonly with acute encephalopathy, displaying
epileptic seizures impaired consciousness or acute behavioural
deterioration. Restoration ofmethylation capacity with appropri-
ate medication may reverse many of the acute clinical signs
(Fischer et al 2014; Huemer et al 2014) (Fig. 2).
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 18 & We strongly recommend im-
mediate treatment with paren-
teral cobalamin in suspected
cases. (Quality of the evi-
dence: moderate)
Recommendation 19 & We recommend consideration
of betaine treatment as soon as
hyperhomocysteinaemia is
proven and normal/low methio-
nine confirmed. (Quality of the
evidence: moderate)
Recommendation 20 & We suggest consideration of ad-
ditional enteral supplemen-
tation with folinic acid or L-
methionine in individual cases.
(Quality of the evidence: low)
Improving the outcome: long-term management
of cobalamin-related combined and isolated remethylation
disorders
Most of the knowledge about the management of remethylation
disorders is derived from the experience with individuals with
the cblC defect, the most frequent of the disorders. In clinical
practice the rarer combined disorders of the cblD-MMA/HC,
cblF and cblJ types as well as the isolated remethylation disor-
ders are generally managed identically but experience
concerning treatment efficacy is considerably less and weaker.
Treatment of individuals with the remethylation disorders
aims to improve clinical features and metabolic abnormalities
by reducing tHcy and normalising Met and—in combined
disorders—MMA (Table 7).
Cobalamin
Cobalamin is the cofactor of methionine synthase. In the
cblC defect, hydroxocobalamin (OHCbl) appears to
be more effective than cyanocobalamin (CNCbl)
(Andersson and Shapira 1998; Bodamer et al 2001).
Froese et al (2010) describe that, e.g. MMAMHC with
the c.482G>A (R161Q) mutation binds OHCbl with more
affinity than CNCbL. The parental route of administration
(IV, SQ or IM) has been proved to be beneficial in pa-
tients with the cblC defect (Van Hove et al 2002), whereas
oral OHCbl alone seems to be ineffective (Brunelli et al
2002; Bartholomew et al 1988; Gold et al 1996; Frattini
et al 2010). Long-term IV application is impracticable and
the subcutaneous route seems to be less effective than IM
injections (Thauvin-Robinet et al 2008). Many centres use
1 mg of parenteral OHCbl daily in neonates (assuming a
body weight of 3 kg, the dosage is 0.33 mg/kg/day). In
the long-term treatment, as patients stabilise, the frequen-
cy of administration is decreased to minimise the frequen-
cy of injections. However, determination of optimal doses
and intervals between injections is hampered by very
great variation in patient features (Dionisi-Vici et al
2013; Ogier de Baulny et al 1998). Some recent reports
suggest that higher OHCbl doses (plasma levels near
1,000,000 pg/ml) can provide a better metabolic control
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and dose escalation seems to be effective in several re-
ports, including a case of pregnancy in a cblC affected
female (Brunel-Guitton et al 2010). In 2002 Van Hove
et al (2002) described a good response to OHCbl dose
escalation regarding metabolic and clinical condition in
two cblC patients presenting with thrombotic microangi-
opathies (TMAs). During 13 years of follow up in a cblC
patient Carrillo-Carrasco et al (2009) observed a consid-
erable dose-dependent reduction of MMA and tHcy plas-
ma levels and an elevation of methionine levels as the
dose of IM OHCbl was increased. Matos et al 2013 per-
formed an open-label study in five cblC patients to deter-
mine the effect of OHCbl dose escalation on the clinical
and biochemical condition. They observed a goodmetabolic
response in 2/5 patients, whereas clinical response was quite
variable and not clearly related to metabolic improvement. In
early onset cblC disease, tHcy mostly cannot be normalised;
levels between 40 and 60 μmol/L are typically reached. In
some late onset patients, tHcy has been normalised.
There is limited experience with OHCbl (1000 μg/day) treat-
ment in cblD-MMA/HC disease but there seems to be a re-
sponse to treatment (Miousse et al 2009; Suormala et al 2004).
Most patients with cblE and cblG disease were treated with OH-
Cbl and seemed to benefit (Huemer et al 2015a, b). As OH-Cbl
is generally used to treat other cobalamin-related remethylation
disorders than cblC disease, no sufficient data is available on the
clinical efficacy of other cobalamin preparations .
In conclusion, OHCbl treatment is usually started at a dos-
age of 1 mg IM daily and then it should be titrated individually
based on metabolic response.
Outcome: survival and severe organ damage
Recommendation 21 & We strongly recommend using
parenteral OHCbl in treating
patients with the cblC defect and
other cobalamin-related reme-
thylation disorders. (Quality of
the evidence: high)
Recommendation 22 & We recommend applying a star-
ting dose of 1000 μg (1 mg)
OHCbl daily given parenterally
in patients with the cblC defect.
This regime has also been ap-
plied in other cobalamin-related
remethylation defects. (Quality
of the evidence: low)
Recommendation 23 & We suggest that the minimum ef-
fectiveOHCbl dose and frequency
of administration should be indi-
vidually titrated. Escalating doses
of OHCbl may result in biochem-
ical improvement; however, sig-
nificant clinical benefit remains to
be proven. Frequency of adminis-
tration of OHCbl ranges between
daily andweeklywithout evidence
of advantage of one over the other.
(Quality of the evidence: low)
Betaine
Betaine derives from choline and is a potent methyl group
donor involved in the process of remethylation of Hcy to
Met via betaine-homocysteine methyltransferase in the liv-
er, thus bypassing the MeCbl-dependent pathway. Betaine
needs to be supplemented orally and decreases Hcy levels.
The knowledge about betaine pharmacokinetics is limited
(Schwahn et al 2003). It has been suggested that frequent
administration of a moderate dose may provide clinical
and biochemical benefit (Ucar et al 2010). Betaine or
OHCbl alone may not result in sufficient metabolic
control, but they seem to have synergistic effects
(Bartholomew et al 1988). Betaine is usually administered
at a dose of up to 250 mg/kg/day in children (Beauchamp
et al 2009; Schiff et al 2011), but has been used at a dose
of 850 mg/kg/day to treat cor pulmonale in a patient with
the cblC defect (Profitlich et al 2009a, b). Betaine has also
been used during pregnancy with no neonatal adverse ef-
fect (Pierre et al 2006). Anhydrous betaine is the preferred
formulation.
Table 7 Recommended treatment of remethylation disorders
Drugs with proven clinical effect Treatments without proven clinical effect To be avoided
Cobalamin related remethylation disorders OHCbl parenteral
Betaine
Folate/folinic acid
L-Carnitine
Methionine*
Nitrous oxide
Protein restriction
MTHFR deficiency Betaine Folinic acid/ 5-Methylfolate*
L-Carnitine
Methionine*
Nitrous oxide
Folic acid
Protein restriction
*Has been applied with clinical benefit in single cases
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Outcome: survival and severe organ damage
Recommendation 24 & We recommend oral betaine
treatment in cblC disease
and other cobalamin-related
remethylat ion disorders
(Quality of the evidence: low)
Recommendation 25 & We suggest that the minimum
effective betaine dose should
be individually titrated to im-
prove the levels of tHcy and
methionine. (Quality of the
evidence: low)
Side effects of treatment with cobalamin and betaine
Few side effects related to cblC disease treatment have been
reported. These are usually scarce and reversible as soon as
the treatment is withdrawn.
OHCbl side effects such as red discoloration of the urine
and skin, hypersensitivity and photosensitivity reactions, nau-
sea, infusion site reactions and headache have rarely been
reported in patients receiving high doses. Mostly, parenteral
OHCbl even in doses as high as 20 mg per day have been
tolerated without side effects (Carrillo-Carrasco et al 2009).
In a single case, teeth discoloration occurred after 1 month
of OHCbl (1 mg/day IM) and folinic acid (10 mg/day) treat-
ment and improved after folinic acid discontinuation
(Augoustides-Savvopoulou et al 1999).
Long-tem follow up case series and case reports indicate
that betaine is generally well tolerated and safe even at high
doses (3–6 g/day in infants; 9 g/day in adults) (Ogier De
Baulny et al 1998; Thauvin-Robinet et al 2008). However,
in a 15-month-old, epileptic crises have been observed soon
after initiation of betaine treatment (250 mg/kg/day) (Enns
et al 1999).
Betaine decreases Hcy levels at the expense of increasing
Met. The clinical relevance of high Met is under discussion
but very high levels have been related to cerebral oedema. In a
10-year-old female with classical homocystinuria plasma Met
increased to >3000 μmoL/L under betaine treatment (200 mg/
kg/day). The girl developed clinical signs and radiological
evidence of cerebral oedema which resolved when betaine
was discontinued and Met levels returned to normal
(Yaghmai et al 2002). Devlin et al (2004) reported on a similar
clinical course in a boy at a plasmaMet level of 1190 μmol/L.
Therefore, caution is required and betaine should immediately
be withdrawn in any case of any symptoms suggesting in-
creased intracranial pressure or very high Met levels
(Lawson-Yuen and Levy 2006).
Folates
Folate has been frequently used as adjunctive therapy in
patients with cblC disease. Folinic acid (5-formyl-THF)
is the most stable form of the reduced vitamin and
crosses the blood brain barrier more efficiently than
folic acid (Spector 1979). Daily doses from 5 to
30 mg, divided in 2–3 administrations/week of folate
or folinic acid (Carrillo-Carrasco et al 2012; Schiff
et al 2011) have been used. In the majority of reported
patients, folic acid rather than folinic acid has been used
in the long-term treatment. In some cases no beneficial
effect of the adjunctive therapy with folic or folinic acid
has been reported (Enns et al 1999; Bartholomew et al
1988; Fischer et al 2014) but no long-term studies have
been performed.
Recommendation 26 & Results failed to demonstrate or
exclude a beneficial or detri-
mental effect of folic and/or
folinic acid as adjunctive thera-
py in patients with cblC disease
and other cobalamin-related
remethylation disorders.
(Quality of the evidence: low)
Levocarnitine
Levocarnitine facilitates the excretion of propionyl
groups and prevents carnitine deficiency, since the de
novo synthesis of carnitine depends on methionine and
may be decreased in cblC patients. Some reports in
literature show no beneficial effect of adding carnitine
to the long-term treatment of cblC disease (Enns et al
1999; Bartholomew et al 1988). There is no clear con-
sensus about the recommended dose and this can range
between 50 and 200 mg/kg/day.
Recommendation 27 & Results failed to demonstrate
or exclude a beneficial or det-
rimental effect of oral carni-
tine as adjunctive therapy in
patients with cblC disease
and other cobalamin-related
remethylation disorders.
(Quality of the evidence: low)
Dietary restrictions
Few reports describe the use of dietary restriction in cblC pa-
tients, mainly with no beneficial effect on metabolic control
J Inherit Metab Dis
(Carrillo-Carrasco et al 2009; Enns et al 1999). Huemer et al
(2005) report significantly lower MMA excretion upon protein
restriction (methionine-free, threonine-free, valine-free,
isoleucine-low formula). However, there is evidence suggesting
a possible role of lowmethionine as a contributing factor for the
pathogenesis of cblC disease (Martinelli et al 2011) and other
remethylation disorders. Met is essential in patients with
remethylation defects and its plasma levels should be main-
tained in the normal range. Patients on protein-restricted diets
had lower height-for-age z-score. Patients consuming medical
foods with presumably lowMet supply had lower head circum-
ference and lower plasma Met concentrations (Manoli et al
2015). For these reasons, methionine-free formulas and protein
restriction leading to low methionine plasma levels is contrain-
dicated in cblC patients (Ogier de Baulny et al 1998; Manoli
et al 2015).
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 28 & We strongly recommend not
to restrict protein in cblC dis-
ease and other remethylation
disorders. (Quality of the evi-
dence: moderate)
Amino acid supplementation
In patients with cblC defects methionine and cysteine supple-
ments are mostly not required to maintain normal plasma
levels of these two amino acids and in a recent retrospective
multicentre study evaluating clinical, biochemical and thera-
peutic measures in 88 cblC patients (Fischer et al 2014) sup-
plemental Met was used only in one patient; cysteine supple-
mentation was never applied. Some patients were treated with
betaine and Met in combination when plasma Met was low
(Smith et al 2006).
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 29 & Met is essential in patients with
remethylation defects and we
recommend maintaining its
plasma levels in the normal
range; if necessary this may be
achieved by oral methionine
supplementation. (Quality of
the evidence: low)
Improving the outcome: long-term management of
MTHFR deficiency
Betaine
In MTHFR deficiency betaine in a variable dose of 100–
250 mg/kg/day in children and 5–20 g/day in adults is used
to increase systemic Met levels. A meta-analysis of case
reports (Diekman et al 2014) revealed that betaine treatment
at a dosage of 100 mg/kg/day or more was clearly associated
with increased survival. Only two of 26 patients died after
initiation of treatment. Furthermore, early treatment was as-
sociated with normal psychomotor development in all five
patients. In contrast, none of the 19 patients in the delayed-
treatment group (untreated patients excluded) had normal
psychomotor development. Nevertheless, psychomotor de-
velopment stabilised or improved in all 17 surviving patients
in whom betaine treatment was initiated late. Anhydrous
betaine is the preferred formulation.
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 30 & We strongly recommend early
treatment with betaine as it
improves clinical outcome
and prevents neurological de-
terioration in MTHFR defi-
ciency. (Quality of the evi-
dence: high)
See also recommendation 13
Folates
In MTHFR deficiency 5-methylTHF synthesis is impaired,
resulting in low levels of methyl-tetrahydrofolate (CH3-
THF) in the central nervous system. There have been some
reports describing the use of folic acid (5–80 mg/day) with
good (Al Tawari et al 2002; Munoz et al 2015) or poor (Holme
and Ronge 1989; Ucar et al 2010) response. A dose–response
relationship was not observed (Holme and Ronge 1989). A
combination of folic and folinic acid was associated with
favourable outcome (Tallur et al 2005; Lossos et al 2014). It
has recently been shown that folic acid may exacerbate cere-
bral CH3-THF deficiency (Hyland et al 2010) and it has there-
fore been suggested to avoid folic acid and preferably use
folinic acid or 5-CH3-THF. However, therapeutic 5-CH3-
THF in a daily dose as high as 45 mg failed to correct the
low CSF levels in a patient withMTHFR deficiency (Knowles
et al 2016; Schiff and Blom 2012). There is at present no
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consensus concerning the most effective dosage of folinic acid
or 5-CH3-THF and the problem of the assumed instability of
5-CH3-THF has not yet been solved.
Outcome: neurocognitive impairment
Recommendation 31 & Results failed to demonstrate
or exclude a beneficial or det-
rimental effect of folic or
folinic acid or 5-CH3THF as
adjunctive therapy to restore
cellular and cerebral folate de-
ficiency in MTHFR deficien-
cy on clinical outcome.
(Quality of the evidence: low).
Other substances
The data basis addressing the efficacy of vitamin B6, cobala-
min, riboflavin and carnitine is not reliable; various dosages
and combinations of these substances have been used and
their clinical efficacy cannot be assessed (Huemer et al 2016).
Methionine supplementation
In a very small number of patients, the clinical condition im-
proved with supplementation of methionine (Schiff et al 2011;
Tortorelli et al 2010), however, the data basis is not reliable
enough to allow delineation of a recommendation.
Improving clinical outcome: management of general
anaesthesia in remethylation disorders
A fatal adverse event was reported in a patient with MTHFR
deficiency anaesthetised with nitrous oxide (N2O) which is a
known inhibitor of methionine synthase (Selzer et al 2003;
Erbe and Salis 2003). In seven patients with the cblC and
one with the cblG defect, propofol was safe and effective as
an induction and maintenance agent for elective short proce-
dures in metabolically and hemodynamically stable patients
(Ktena et al 2015).
Recommendation 32 & We strongly recommend against
the use of nitrous oxide in pa-
tients with remethylation disor-
ders. (Quality of the evidence:
high)
Improving clinical outcome: management of pregnancy
in remethylation disorders
There are only three reported cases of pregnancies in
women with the cblC defect and thus no recommenda-
tions can be delineated. An asymptomatic woman was
identified when low carnitine levels were found in her
healthy child’s newborn screening sample (Lin et al
2009). Brunel-Guitton et al (2010) describe successful
outcome of a pregnancy in a treated woman with the
cblC defect. Acetylsalicylic acid at the antiplatelet oral
dose of 80 mg/day was applied during pregnancy and
delivery and specific treatment with OHCbl, folic acid
and carnitine was started at 15 weeks of gestation. The
OHCbl and carnitine administration was adjusted to
maintain a decrease of tHcy and an increase of total
carnitine plasma levels. Recently a woman with late-
onset cblC, also treated from the 15th week of gestation
and giving birth to a healthy child has been reported
(Liu et al 2015). So far, pregnancies in women with
other remethylation defects have not been reported.
Closing remarks
These guidelines are the result of the evaluation of
available information from the literature based on the
GRADE methodology and are aimed at delivering rec-
ommendations based on the best available data. The
rarity of cobalamin-related remethylation disorders and
MTHFR deficiency, the absence of larger data samples
from international registries until recently and data
mainly derived from case reports, case series or expert
opinion results in a low quality of the evidence for
several of the recommendations made. The working
group responsible for this guideline commits itself to
revise this work in the future.
Acknowledgments We gratefully acknowledge the support from Prof.
Brian Fowler who critically revised the manuscript. We thank Marike
Gronendijk for her ongoing support of our work.
Compliance with Ethical Standards
Conflict of interest The authors of this guideline declare no competing
interests but disclose the following: MRB has received financial support
for attending E-HOD steering committee meetings from Orphan Europe.
MRB and MH have received support from Milupa Metabolics for travel
grants to develop a quality of life assessment tool for patients with intox-
ication type metabolic diseases. Charles University in Prague-First
Faculty of Medicine received support from the Recordati Rare Disease
Foundation for organizing an educational course on homocystinurias and
methylation defects. MH, MRB, CDV, HB received speakers honoraria
J Inherit Metab Dis
for their contribution to this educational course. The development of this
guideline was part of the BEuropean network and registry for
homocystinurias and methylation defects (EHOD) project^
(No.2012_12_02) which has received funding from the European
Union in the framework of the Health Program. This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Al Essa MA, Al Amir A, Rashed M et al (1999) Clinical, fluorine-18
labeled 2-fluoro-2-deoxyglucose positron emission tomography of
the brain, MR spectroscopy, and therapeutic attempts in methylene-
tetrahydrofolate reductase deficiency. Brain Dev 21:345–349
Al Tawari AA, Ramadan DG, Neubauer D, Heberle LC, Al Awadi F
(2002) An early onset form methylenetetrahydrofolate reductase
deficiency: a report of a family fromKuwait. Brain Dev 24:304–309
Alfadhel M, Lillquist YP, Davis C, Junker AK, Stockler-Ipsiroglu S
(2011) Eighteen-year follow-up of a patient with cobalamin F dis-
ease (cblF): report and review. Am J Med Genet 155A:2571–2577
Andersson HC, Shapira E (1998) Biochemical and clinical response to
hydroxocobalamin versus cyanocobalamin treatment in patients
with methylmalonic acidemia and homocystinuria (cblC). J Pediatr
132:121–124
Andersson HC, Marble M, Shapira E (1999) Long-term outcome in treat-
ed combined methylmalonic acidemia and homocystinemia. Genet
Med 1:146–150
AraiM, Osaka H (2011) Acute leukoencephalopathy possibly induced by
phenytoin intoxication in an adult patient with methylenetetrahydro-
folate reductase deficiency. Epilepsia 52:e58–61
Armour CM, Brebner A, Watkins D, Geraghty MT, Chan A, Rosenblatt
DS (2013) A patient with an inborn error of vitaminB12metabolism
(cblF) detected by newborn screening. Pediatrics 132:e257–261
Arn PH, Williams CA, Zori RT, Driscoll DJ, Rosenblatt DS (1998)
Methylenetetrahydrofolate reductase deficiency in a patient with
phenotypic findings of Angelman syndrome. Am J Med Genet 77:
198–200
Atkinson C, Miousse IR, Watkins D, Rosenblatt DS, Raiman JA (2014)
Clinical, biochemical end molecular presentation in a patient with
the CblD Homocystinuria error of cobalamin metabolism. JIMD
Rep 17:77–81
Augoustides-Savvopoulou P, Mylonas I, Sewell AC, Rosenblatt DS
(1999) Reversible dementia in an adolescent with cblC disease:
clinical heterogeneity within the same family. J Inherit Metab Dis
22:756–758
Backe PH, Ytre-Arne M, Røhr AK et al (2013) Novel deletion mutation
identified in a patient with late-onset combined methylmalonic
acidemia and homocystinuria, cblC Type. JIMD Rep 11:79–85
Bartholomew DW, Batshaw ML, Allen RH et al (1988) Therapeutic
approaches to cobalamin-C methylmalonic acidemia and
homocystinuria. J Pediatr 112:32–9
Baumgartner ER, Wick H, Linnell JC, Gaull GE, Bachmann C,
Steinmann B (1979a) Congenital defect in intracellular cobalamin
metabolism resulting in homocystinuria and methylmalonic
aciduria. II. Biochemical investigations. Helv Paediatr Acta 34:
483–496
Baumgartner ER, Wick H, Maurer R, Egli N, Steinmann B (1979b)
Congenital defect in intracellular cobalamin metabolism resulting
in homocysteinuria and methylmalonic aciduria. I. Case report and
histopathology. Helv Paediatr Acta 34:465–482
Beauchamp MH, Anderson V, Boneh A (2009) Cognitive and social
profiles in two patients with cobalamin C disease. J Inherit Metab
Dis 32:327–334
Bellini C, Cerone R, Bonacci W et al (1992) Biochemical diagnosis and
outcome of 2 years treatment in a patient with combined
methylmalonic aciduria and homocystinuria. Eur J Pediatr 151:
818–820
Ben-Omran TI, Wong H, Blaser S, Feigenbaum A (2007) Late-onset
cobalamin-C disorder: a challenging diagnosis. Am J Med Genet
143A:979–984
Ben-Shachar S, Zvi T, Rolfs A et al (2012) A founder mutation causing a
severe methylenetetrahydrofolate reductase (MTHFR) deficiency in
Bukharian Jews. Mol Genet Metab 107:608–610
Biancheri R, Cerone R, SchiaffinoMC et al (2001) Cobalamin (Cbl) C/D
deficiency: clinical, neurophysiological and neuroradiologic find-
ings in 14 cases. Neuropediatrics 32:14–22
Biancheri R, Cerone R, Rossi A et al (2002) Early-onset cobalamin C/D
deficiency: epilepsy and electroencephalographic features. Epilepsia
43:616–622
Biotti D, Esteban-Mader M, Diot E et al (2014) Clinical reasoning: a
young woman wi th rap id men t a l de te r io ra t ion and
leukoencephalopathy: a treatable cause. Neurology 83:e182–186
Birnbaum T, Blom HJ, Prokisch H, Hartig M, Klopstock T (2008)
Methylenetetrahydrofolate reductase deficiency (homocystinuria
type II) as a rare cause of rapidly progressive tetraspasticity
and psychosis in a previously healthy adult. J Neurol 255:
1845–1846
Bishop L, Kanoff R, Charnas L, Krenzel C, Berry SA, Schimmenti LA
(2008) Severe asymptomatic methylenetetrahydrofolate reductase
(MTHFR) deficiency: a case report of nonclassical homocystinuria.
J Child Neurol 23:823–828
Bodamer OA, Rosenblatt DS, Appel SH, Beaudet AL (2001) Adult-onset
combined methylmalonic aciduria and homocystinuria (cblC).
Neurology 56:1113
Bonafede L, Ficicioglu CH, Serrano L, Han G, Morgan J, Mills MD
(2015) Cobalamin C deficiency shows a rapidly progressing
maculopathy with severe photoreceptor and ganglion cell loss.
IOVS 56:7876
Bowron A, Barton A, Scott J, Stansbie D (2005) Blood spot homocyste-
ine: a feasibility and stability study. Clin Chem 51:257–258
Brandstetter Y, Weinhouse E, Splaingard ML, Tang TT (1990) Cor
pulmonale as a complication of methylmalonic acidemia and
homocystinuria (Cbl-C type). Am J Med Genet 36:167–171
Brooks BP, Thompson AH, Sloan JL et al (2016) Ophthalmic manifesta-
tions and long-term visual outcomes in patients with cobalamin C
deficiency. Ophthalmology 123:571–82
Broomfield A, Abulhoul L, Pitt W, Jameson E, ClearyM (2014) Reversal
of respiratory failure in both neonatal and late onset isolated
remethylation disorders. JIMD Rep 16:51–56
Brunel-Guitton C, Costa T, Mitchell GA, Lambert M (2010) Treatment of
cobalamin C (cblC) deficiency during pregnancy. J Inherit Metab
Dis 33:409–412
Brunelli SM, Meyers KE, Guttenberg M, Kaplan P, Kaplan BS (2002)
Cobalamin C deficiency complicated by an atypical glomerulopa-
thy. Pediatr Nephrol 17:800–803
Burda P, Kuster A, Hjalmarson O, Suormala T, Bürer C, Lutz S (2015)
Characterization and review of MTHFD1 deficiency: four new pa-
tients, cellular delineation and response to folic and folinic acid
treatment. J Inherit Metab Dis 38:863–872
J Inherit Metab Dis
Cappuccio G, Cozzolino C, Frisso G (2014) Pearls & oysters: familial
epileptic encephalopathy due to methylenetetrahydrofolate reduc-
tase deficiency. Neurology 83:e41–44
Carmel R, Bedros AA, Mace JW, Goodman SI (1980) Congenital
methylmalonic aciduria–homocystinuria with megaloblastic ane-
mia: observations on response to hydroxocobalamin and on the ef-
fect of homocysteine and methionine on the deoxyuridine suppres-
sion test. Blood 55:570–579
Carmel R, Watkins D, Goodman SI, Rosenblatt DS (1988) Hereditary
defect of cobalamin metabolism (cblG mutation) presenting as a
neurologic disorder in adulthood. N Engl J Med 318:1738–1741
Carrillo-Carrasco N, Venditti CP (2012a) Combined methylmalonic
acidemia and homocystinuria, cblC type. II. Complications, patho-
physiology, and outcomes. J Inherit Metab Dis 35:103–114
Carrillo-Carrasco N, Chandler RJ, Venditti CP (2012b) Combined
methylmalonic acidemia and homocystinuria, cblC type. I. Clinical
presentations, diagnosis and management. J Inherit Metab Dis 35:
91–102
Carrillo-Carrasco N, Adams D, Venditti CP (2013) Disorders of
Intracellular Cobalamin Metabolism. In: Pagon RA, Adam MP,
Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD,
Fong CT, Mefford HC, Smith RJH, Stephens K, editors.
GeneReviews® [Internet]. Seattle (WA): University of
Washington, Seattle. 2008 Feb 25 [updated 2013 Nov 21]
Carrillo-Carrasco N, Sloan J, Valle D, Hamosh A, Venditti CP (2009)
Hydroxocobalamin dose escalation improves metabolic control in
cblC. J Inherit Metab Dis 32:728–731
Cerone R, Schiaffino MC, Caruso U, Gatti R (2000) Facial anomalies in
combined methylmalonic aciduria and homocystinuria. Am J Med
Genet 6:87
Chang JT, Chen YY, Liu TT, Liu MY, Chiu PC (2011) Combined
methylmalonic aciduria and homocystinuria cblC type of a
Taiwanese infant with c.609G>A and C.567dupT mutations in the
MMACHC gene. Pediatr Neonatol 52:223–226
Clayton PT, Smith I, Harding B, Hyland K, Leonard JV, Leeming RJ
(1986) Subacute combined degeneration of the cord, dementia and
parkinsonism due to an inborn error of folate metabolism. J Neurol
Neurosurg Psychiatry 49:920–927
Coelho D, Suormala T, Stucki M et al (2008) Gene identification for the
cblD defect of vitamin B12 metabolism. N Engl J Med 358:1454–
1464
Coelho D, Kim JC, Miousse IR et al (2012)Mutations in ABCD4 cause a
new inborn error of vitamin B12 metabolism. Nat Genet 44:1152–
1155
Cogan DG, Schulman J, Porter RJ, Mudd SH (1980) Epileptiform ocular
movements with methylmalonic aciduria and homocystinuria. Am J
Ophthalmol 90:251–253
Collison FT, Xie YA, Gambin T et al (2015) Whole exome sequencing
identifies an adult-onset case of methylmalonic aciduria and
homocystinuria type C (cblC) with non-syndromic bull’s eye
maculopathy. Ophthalmic Genet 36:270–275
Carrillo-Carrasco N, Chandler RJ, Venditti CP (2012b) Combined
methylmalonic acidemia and homocystinuria, cblC type. I. Clinical
presentations, diagnosis and management. J Inherit Metab Dis 35:
91–102
D’Aco KE, Bearden D, Watkins D, Hyland K, Rosenblatt DS, Ficicioglu
C (2014) Severe 5,10- Methyltetrahydrofolate reductase deficiency
and two MTHFR variants in an adolescent with progressive myo-
clonic epilepsy. Pediatr Neurol 51:266–270
D’Alessandro G, Tagariello T, Piana G (2010) Oral and craniofacial find-
ings in a patient with methylmalonic aciduria and homocystinuria:
review and a case report. Minerva Stomatol 59:129–137
De Bie I, Nizard SD, Mitchell GA (2009) Fetal dilated cardiomyopathy:
an unsuspected presentation of methylmalonic aciduria and
hyperhomocystinuria, cblC type. Prenat Diagn 29:266–270
Devlin AM, Hajipour L, Gholkar A, Fernandes H, Ramesh V, Morris AA
(2004) Cerebral edema associated with betaine treatment in classical
homocystinuria. J Pediatr 144:545–548
Diekman EF, de Koning TJ, Verhoeven-Duif NM, Rovers MM, van
Hasselt PM (2014) Survival and psychomotor development with
early betaine treatment in patients with severe methylenetetrahydro-
folate reductase deficiency. JAMA Neurol 71:188–194
Dionisi-Vici C, Martinelli D, Ceravolo F, Boenzi S, Pastore A (2013)
Optimizing the dose of hydroxocobalamin in cobalamin C (cblC)
defect. Mol Genet Metab 109:329–330
Ellaway C, Christodoulou J, Kamath R, Carpenter K, Wilcken B (1998)
The association of protein-losing enteropathy with cobalamin C de-
fect. J Inherit Metab Dis 21:17–22
Engelbrecht V, Rassek M, Huismann J, Wendel U (1997) MR and proton
MR spectroscopy of the brain in hyperhomocysteinemia caused by
methylenetetrahydrofolate reductase deficiency. AJNR Am J
Neuroradiol 18:536–539
Enns GM, Barkovich AJ, Rosenblatt DS et al (1999) Progressive neuro-
logical deterioration and MRI changes in cblC methylmalonic
acidaemia treated with hydroxocobalamin. J Inherit Metab Dis 22:
599–607
Erbe RW, Salis RJ (2003) Severe methylenetetrahydrofolate reductase
deficiency, methionine synthase, and nitrous oxide–a cautionary
tale. N Engl J Med 349:5–6
Fischer S, Huemer M, Baumgartner M et al (2014) Clinical presentation
and outcome in a series of 88 patients with the cblC defect. J Inherit
Metab Dis 37:831–840
Fowler B (2005) Homocysteine: overview of biochemistry, molecular
biology, and role in disease processes. Semin Vasc Med 5:77–86
Fowler B, Jakobs C (1998) Post- and prenatal diagnostic methods for the
homocystinurias. Eur J Pediatr 157:S88–93
Frattini D, Fusco C, Ucchino V, Tavazzi B, Della Giustina E (2010) Early
onset methylmalonic aciduria and homocystinuria cblC type with
demyelinating neuropathy. Pediatr Neurol 43:135–138
Froese DS, Healy S, McDonald M et al (2010) Thermolability of mutant
MMACHC protein in the vitamin B12-responsive cblC disorder.
Mol Genet Metab 100:29–36
Froese DS, Huemer M, Suormala T et al (2016) Mutation update and
review of severe MTHFR deficiency. Hum Mutat. doi:10.1002
/humu.22970
Fuchs LR, Robert M, Ingster-Moati I et al (2012) Ocular manifestations
of cobalamin C type methylmalonic aciduria with homocystinuria. J
AAPOS 16:370–375
Gaillard MC, Matthieu JM, Borruat FX (2008) Retinal dysfunction in
combined methylmalonic aciduria and homocystinuria (Cblc) dis-
ease: a spectrum of disorders. Klin Monbl Augenheilkd 225:491
Gailus S, Suormala T, Malerczyk-Aktas AG, Toliat MR, Wittkampf T,
Stucki M (2010) A novel mutation in LMBRD1 causes the cblF
defect of vitamin B(12) metabolism in a Turkish patient. J Inherit
Metab Dis 33:17–24
Geraghty MT, Perlman EJ, Martin LS et al (1992) Cobalamin C defect
associated with hemolytic-uremic syndrome. J Pediatr 120:934–937
Gerth C, Morel CF, Feigenbaum A, Levin AV (2008) Ocular phenotype
in patients with methylmalonic aciduria and homocystinuria, cobal-
amin C type. J AAPOS 12:591–596
Gizicki R, Robert MC, Gómez-López L et al (2014) Long-term visual
outcome of methylmalonic aciduria and homocystinuria, cobalamin
C type. Ophthalmology 121:381–386
Gold R, Bogdahn U, Kappos L et al (1996) Hereditary defect of cobala-
min metabolism (homocystinuria and methylmalonic aciduria) of
juvenile onset. J Neurol Neurosurg Psychiatry 60:107–108
Goodman SI, Moe PG, Hammond KB, Mudd SH, Uhlendorf BW (1970)
Homocystinuria with methylmalonic aciduria: two cases in a
sibship. Biochem Med 4:500–515
J Inherit Metab Dis
Goyette P, Sumner JS, Milos R et al (1994) Human methylenetetrahydro-
folate reductase: isolation of cDNA, mapping and mutation identi-
fication. Nat Genet 7:195–200
Goyette P, Frosst P, Rosenblatt DS, Rozen R (1995) Seven novel muta-
tions in the methylenetetrahydrofolate reductase gene and genotype/
phenotype correlations in severe methylenetetrahydrofolate reduc-
tase deficiency. Am J Hum Genet 56:1052–1059
Goyette P, Christensen B, Rosenblatt DS, Rozen R (1996) Severe and
mild mutations in cis for the methylenetetrahydrofolate reductase
(MTHFR) gene, and description of five novel mutations in
MTHFR. Am J Hum Genet 59:1268–1275
Grangé S, Bekri S, Artaud-Macari E et al (2015) Adult-onset renal throm-
botic microangiopathy and pulmonary arterial hypertension in co-
balamin C deficiency. Lancet 386:1011–1012
Grant LW, McCandless SE, Traboulsi EI (2009) Maculopathy due to
cobalamin C (cblC) disease in an Amish child. J Pediatr
Ophthalmol Strabismus. doi:10.3928/01913913-20090918-10
Greitz D (2007) Paradigm shift in hydrocephalus research in legacy of
Dandy’s pioneering work: rationale for third ventriculostomy in
communicating hydrocephalus. Childs Nerv Syst 23:487–489
Grünert SC, Fowler B, Superti-Furga A, Sass JO, Schwab KO (2011)
Hyperpyrexia resulting in encephalopathy in a 14-month-old patient
with cblC disease. Brain Dev 33:432–436
Guigonis V, Frémeaux-Bacchi V, Giraudier S et al (2005) Late-onset
thrombocytic microangiopathy caused by cblC disease: association
with a factor H mutation. Am J Kidney Dis 45:588–595
Gulati S, Chen Z, Brody LC, Rosenblatt DS, Banerjee R (1997) Defects
in auxiliary redox proteins lead to functional methionine synthase
deficiency. J Biol Chem 272:19171–19175
Gündüz M, Ekici F, Özaydın E, Ceylaner S, Perez B (2014) Reversible
pulmonary arterial hypertension in cobalamin-dependent cobalamin
C disease due to a novel mutation in the MMACHC gene. Eur J
Pediatr 173:1707–1710
Guyatt G, Oxman AD, Akl EA et al (2011a) GRADE guidelines: 1.
Introduction-GRADE evidence profiles and summary of findings
tables. J Clin Epidemiol 64:383–94
Guyatt GH, Oxman AD, Kunz R et al (2011b) GRADE guidelines: 2.
Framing the question and deciding on important outcomes. J Clin
Epidemiol 64:395–400
Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A
(2011c) GRADE guidelines: 3. Rating the quality of evidence. J
Clin Epidemiol 64:380–382
Guyatt GH, Norris SL, Schulman S et al (2012) Methodology for the
development of antithrombotic therapy and prevention of thrombo-
sis guidelines: antithrombotic therapy and prevention of thrombosis,
9th ed: American college of chest physicians evidence-based clinical
practice guidelines. Chest 141:53S–70S
Haan EA, Rogers JG, Lewis GP, Rowe PB (1985) 5,10-
Methylenetetrahydrofolate reductase deficiency. Clinical and bio-
chemical features of a further case. J Inherit Metab Dis 8:53–57
Hannibal L, Kim J, Brasch NE et al (2009) Processing of alkylcobalamins
in mammalian cells: a role for the MMACHC (cblC) gene product.
Mol Genet Metab 97:260–266
Harding CO, Arnold G, Barness LA, Wolff JA, Rosenblatt DS
(1997) Functional methionine synthase deficiency due to
cblG disorder: a report of two patients and a review. Am J
Med Genet 71:384–390
Harpey JP, Rosenblatt DS, Cooper BA, Le Moël G, Roy C, Lafourcade J
(1981) Homocystinuria caused by 5,10-methylenetetrahydrofolate
reductase deficiency: a case in an infant responding to methionine,
folinic acid, pyridoxine, and vitamin B12 therapy. J Pediatr 98:275–
278
Haworth JC, Dilling LA, Surtees RA et al (1993) Symptomatic and
asymptomatic methylenetetrahydrofolate reductase deficiency in
two adult brothers. Am J Med Genet 45:572–575
Holme E, Ronge E (1989) Betaine for treatment of homocystinuria
caused by methylenetetrahydrofolate reductase deficiency. Arch
Dis Child 64:1061–1064
Howard R, Frieden IJ, Crawford D et al (1997) Methylmalonic acidemia,
cobalamin C type, presenting with cutaneous manifestations. Arch
Dermatol 133:1563–1566
Huemer M, Simma B, Fowler B, Suormala T, Bodamer OA, Sass JO
(2005) Prenatal and postnatal treatment in cobalamin C defect. J
Pediatr 147:469–472
Huemer M, Scholl-Bürgi S, Hadaya K et al (2014) Three new cases of
late-onset cblC defect and review of the literature illustrating when
to consider inborn errors of metabolism beyond infancy. Orphanet J
Rare Dis 15:161
Huemer M, Bürer C, Ješina P et al (2015a) Clinical onset and course,
response to treatment and outcome in 24 patients with the cblE or
cblG remethylation defect complemented by genetic and in vitro
enzyme study data. J Inherit Metab Dis 38:957–967
Huemer M, Kožich V, Rinaldo P et al (2015b) Newborn screening for
homocystinurias and methylation disorders: systematic review and
proposed guidelines. J Inherit Metab Dis 38:1007–1019
Huemer M, Mulder-Bleile R, Burda P et al (2016) Clinical pattern, mu-
tations and in vitro residual activity in 33 patients with severe 5, 10
methylenetetrahydrofolate reductase (MTHFR) deficiency. J Inherit
Metab Dis 39:115–124
Hyland K, Smith I, Bottiglieri Tet al (1988) Demyelination and decreased
S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase
deficiency. Neurology 38:459–462
Hyland K, Shoffner J, Heales SJ (2010) Cerebral folate deficiency. J
Inherit Metab Dis 33:563–570
Iodice FG, Di Chiara L, Boenzi S et al (2013) Cobalamin C defect pre-
senting with isolated pulmonary hypertension. Pediatrics 132:e248–
251
Jusufi J, Suormala T, Burda P, Fowler B, Froese DS, Baumgartner MR
(2014) Characterization of functional domains of the cblD
(MMADHC) gene product. J Inherit Metab Dis 37:841–849
Kanwar YS, Manaligod JR, Wong PW (1976) Morphologic studies in a
patient with homocystinuria due to 5, 10-methylenetetrahydrofolate
reductase deficiency. Pediatr Res 10:598–609
Kim J, Gherasim C, Banerjee R (2008) Decyanation of vitamin B12 by a
trafficking chaperone. Proc Natl Acad Sci U S A 23:14551–14554
Kim JC, Lee NC, Hwu PW et al (2012) Late onset of symptoms in an
atypical patient with the cblJ inborn error of vitamin B12 metabo-
lism: diagnosis and novel mutation revealed by exome sequencing.
Mol Genet Metab 107:664–668
Kind T, Levy J, Lee M, Kaicker S, Nicholson JF, Kane SA (2002)
Cobalamin C disease presenting as hemolytic-uremic syndrome in
the neonatal period. J Pediatr Hematol Oncol 24:327–329
King GD, Rosene DL, Abraham CR (2012) Promoter methylation and
age-related downregulation of Klotho in rhesus monkey. Age 34:
1405–1419
Knowles L, Morris AA, Walter JH (2016) Treatment with mefolinate (5-
Methyltetrahydrofolate), but not folic acid or folinic acid, leads to
measurable 5-methyltetrahydrofolate in cerebrospinal fluid in meth-
ylenetetrahydrofolate reductase deficiency. JIMD Rep 29:103–107
Kömhoff M, Roofthooft MT,Westra D et al (2013) Combined pulmonary
hypertension and renal thrombotic microangiopathy in cobalamin C
deficiency. Pediatrics 132:e540–544
Ktena YP, Ramstad T, Baker EH et al (2015) Propofol administration in
patients with methylmalonic acidemia and intracellular cobalamin
metabolism disorders: a review of theoretical concerns and clinical
experiences in 28 patients. J Inherit Metab Dis 38:847–853
Kubová H, Folbergrová J, Mares P (1995) Seizures induced by homo-
cysteine in rats during ontogenesis. Epilepsia 36:750–756
Kvittingen EA, Spangen S, Lindemans J, Fowler B (1997) Methionine
synthase deficiency without megaloblastic anaemia. Eur J Pediatr
156:925–930
J Inherit Metab Dis
la Marca G, Malvagia S, Pasquini E, Innocenti M, Donati MA,
Zammarchi E (2007) Rapid 2nd-tier test for measurement of 3-
OH-propionic andmethylmalonic acids on dried blood spots: reduc-
ing the false-positive rate for propionylcarnitine during expanded
newborn screening by liquid chromatography-tandem mass spec-
trometry. Clin Chem 53:1364–1369
Lawson-Yuen A, Levy HL (2006) The use of betaine in the treatment of
elevated homocysteine. Mol Genet Metab 88:201–207
Leclerc D, Wilson A, Dumas R et al (1998) Cloning and mapping of a
cDNA for methionine synthase reductase, a flavoprotein defective in
patients with homocystinuria. Proc Natl Acad Sci 95:3059–3064
Lerner-Ellis JP, Tirone JC, Pawelek PD et al (2006) Identification of the
gene responsible for methylmalonic aciduria and homocystinuria,
cblC type. Nat Genet 38:93–100
Lerner-Ellis JP, Anastasio N, Liu J et al (2009) Spectrum of mutations in
MMACHC, allelic expression, and evidence for genotype-
phenotype correlations. Hum Mutat 30:1072–1081
Lesesve JF, Latger-Cannard V (2013) Crucial microscopic features lead-
ing to diagnosis of cobalamin C deficiency in a new-born. Br J
Haematol 161:608
Levy HL, Mudd SH, Schulman JD, Dreyfus PM, Abeles RH (1970) A
derangement in B12 metabolism associated with homocystinemia,
cystathioninemia, hypomethioninemia and methylmalonic aciduria.
Am J Med 48:390–397
Li YN, Gulati S, Baker PJ, Brody LC, Banerjee R, Kruger WD (1996)
Cloning, mapping and RNA analysis of the human methionine syn-
thase gene. Hum Mol Genet 5:1851–1858
Lin HJ, Neidich JA, Salazar D et al (2009) Asymptomatic maternal com-
bined homocystinuria and methylmalonic aciduria (cblC) detected
through low carnitine levels on newborn screening. J Pediatr 155:
924–927
Liu Y, Wang Q, Li X, Ding Y, Song J, Yang Y (2015) First Chinese case
of successful pregnancy with combined methylmalonic aciduria and
homocystinuria, cblC type. Brain Dev 37:286–291
Longo D, Fariello G, Dionisi-Vici C et al (2005) MRI and 1H-MRS
findings in early-onset cobalamin C/D defect. Neuropediatrics 36:
366–372
Lossos A, Omri T, Tsipi M, Vardiella M, Rima R, Daniel L (2014) Severe
methylenetetrahydrofolate reductase deficiency clinical clues to a
potentially treatable cause of adult onset hereditary spastic paraple-
gia. JAMA Neurol 71:901–904
Maamar M, Mezalek ZT, Harmouche H, Adnaoui M, Aouni M,Maaouni
A (2008) Contribution of spinal MRI for unsuspected cobalamin
deficiency in isolated sub-acute combined degeneration. Eur J
Intern Med 19:143–145
Mah W, Deme JC, Watkins D et al (2013) Subcellular location of
MMACHC andMMADHC, two human proteins central to intracel-
lular vitamin B(12) metabolism. Mol Gen Metab 108:112–118
Malvagia S, Haynes CA, Grisotto L et al (2015) Heptadecanoylcarnitine
(C17) a novel candidate biomarker for newborn screening of
propionic and methylmalonic acidemias. Clin Chim Acta 23:342–
348
Manoli I, Myles JG, Sloan JL et al (2015) A critical reappraisal of dietary
practices in methylmalonic acidemia raises concerns about the safe-
ty of medical foods. Part 2: cobalamin C deficiency. Genet Med.
doi:10.1038/gim.2015.107
Mares P, Folbergrová J, Langmeier M, Haugvicová R, Kubová H (1997)
Convulsant action of D, L-homocysteic acid and its stereoisomers in
immature rats. Epilepsia 38:767–776
Martinelli D, Deodato F, Dionisi-Vici C (2011) Cobalamin C defect:
natural history, pathophysiology, and treatment. J Inherit Metab
Dis 34:127–135
Matos IV, Castejón E, Meavilla S et al (2013) Clinical and biochemical
outcome after hydroxocobalamin dose escalation in a series of pa-
tients with cobalamin C deficiency. Mol Genet Metab 109:360–365
McCully KS (1969) Vascular pathology of homocysteinemia: implica-
tions for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–
128
McCully KS (1992) Homocystinuria, arteriosclerosis, methylmalonic
aciduria, and methyltransferase deficiency: a key case revisited.
Nutr Rev 50:7–12
McHugh D, Cameron CA, Abdenur JE et al (2011) Clinical validation of
cutoff target ranges in newborn screening of metabolic disorders by
tandem mass spectrometry: a worldwide collaborative project.
Genet Med 13:230–254
Menni F, Testa S, Guez S, Chiarelli G, Alberti L, Esposito S (2012)
Neonatal atypical hemolytic uremic syndrome due to
methylmalonic aciduria and homocystinuria. Pediatr Nephrol 27:
1401–1405
Merinero B, Pérez-Cerdá C, Garcia MJ et al (1998) Reliability of bio-
chemical parameters used in prenatal diagnosis of combined
methylmalonic aciduria and homocystinuria. Prenat Diagn 18:
947–952
Michot JM, Sedel F, Giraudier S, Smiejan JM, Papo T (2008) Psychosis,
paraplegia and coma revealing methylenetetrahydrofolate reductase
deficiency in a 56-year-old woman. J Neurol Neurosurg Psychiatry
79:963–964
Miousse IR, Watkins D, Coelho D et al (2009) Clinical and molecular
heterogeneity in patients with the cblD inborn error of cobalamin
metabolism. J Pediatr 154:551–556
Miousse IR,WatkinsD, Rosenblatt DS (2011)Novel splice site mutations
and a large deletion in three patients with the cblF inborn error of
vitamin B12 metabolism. Mol Genet Metab 102:505–507
Mitchell GA, Watkins D, Melançon SB et al (1986) Clinical heterogene-
ity in cobalamin C variant of combined homocystinuria and
methylmalonic aciduria. J Pediatr 108:410–415
Moat SJ, Bonham JR, Tanner MS, Allen JC, Powers HJ (1999)
Recommended approaches for the laboratory measurement of ho-
mocysteine in the diagnosis and monitoring of patients with hyper-
homocysteinaemia. Ann Clin Biochem 36:372–379
Morath MA, Okun JG, Müller IB, Sauer SW, Hörster F, Hoffmann GF,
Kölker S (2008) Neurodegeneration and chronic renal failure in
methylmalonic aciduria—a pathophysiological approach. J Inherit
Metab Dis 31:35–43
Morath MA, Hörster F, Sauer SW (2013) Renal dysfunction in
methylmalonic acidurias: review for the pediatric nephrologist.
Pediatr Nephrol 28:227–235
Morel C, Watkins D, Scott P, Rinaldo P, Rosenblatt DS (2005) Prenatal
diagnosis for methylmalonic acidemia and inborn errors of vitamin
B12 metabolism and transport. Mol Genet Metab 86:160–171
Morel CF, Lerner-Ellis JP, Rosenblatt DS (2006) Combined
methylmalonic aciduria and homocystinuria (cblC): phenotype-
genotype correlations and ethnic-specific observations. Mol Genet
Metab 88:315–321
Moreno-Garcia MA, Pupavac M, Rosenblatt DS, Tremblay ML, Jerome-
Majewska LA (2014) The Mmachc gene is required for pre-
implantation embryogenesis in the mouse. Mol Genet Metab 112:
198–204
Mudd SH (2011) Hypermethioninemias of genetic and non-genetic ori-
gin: a review. Am J Med Genet C Semin Med Genet 15:3–32
Mudd SH, Freeman JM (1974) N-5,10-methylenetetrahydrofolate reduc-
tase deficiency and schizophrenia: a working hypothesis. J Psychiatr
Res 11:259–262
Müller P, Horneff G, Hennermann JB (2007) A rare inborn error of
intracellular processing of cobalamine presenting with
microcephalus and megaloblastic anemia: a report of 3 children.
Klin Padiatr 219:361–367
Munoz T, Patel J, Badilla-Porras R, Kronick J, Mercimek-Mahmutoglu S
(2015) Severe scoliosis in a patient with severe methylenetetrahy-
drofolate reductase deficiency. Brain Dev 37:168–170
J Inherit Metab Dis
Nishimura M, Yoshino K, Tomita Y et al (1985) Central and peripheral
nervous system pathology of homocystinuria due to 5,10-methy-
lenetetrahydrofolate reductase deficiency. Pediatr Neurol 1:375–378
Nogueira C, Aiello C, Cerone R et al (2008) Spectrum of MMACHC
mutations in Italian and Portuguese patients with combined
methylmalonic aciduria and homocystinuria, cblC type. Mol Genet
Metab 93:475–480
Ogier de Baulny H, Gérard M, Saudubray JM, Zittoun J (1998)
Remethylation defects: guidelines for clinical diagnosis and treat-
ment. Eur J Pediatr 157:S77–83
Olteanu H, Banerjee R (2001) Human methionine synthase reductase, a
soluble P-450 reductase-like dual flavoprotein, is sufficient for
NADPH-dependent methionine synthase activation. J Biol Chem
276:35558–35563
Pasquier F, Lebert F, Petit H, Zittoun J, Marquet J (1994)
Methylenetetrahydrofolate reductase deficiency revealed by a neu-
ropathy in a psychotic adult. J Neurol Neurosurg Psychiatry 57:765–
756
Pastore A, Martinelli D, Piemonte F et al (2014) Glutathione metabolism
in cobalamin deficiency type C (cblC). J Inherit Metab Dis 37:125–
129
Patton N, Beatty S, Lloyd IC, Wraith JE (2000) Optic atrophy in associ-
ation with cobalamin C (cblC) disease. Ophthalmic Genet 21:151–
154
Paul EA, Guttenberg M, Kaplan P et al (2013) Atypical glomerulopathy
associated with the cblE inborn error of vitamin B12 metabolism.
Pediatr Nephrol 28:1135–1139
Pierre G, Gissen P, Chakrapani A, McDonald A, Preece M, Wright J
(2006) Successful treatment of pyridoxine-unresponsive
homocystinuria with betaine in pregnancy. J Inherit Metab Dis 29:
688–689
Powers JM, Rosenblatt DS, Schmidt RE et al (2001) Neurological and
neuropathologic heterogeneity in two brothers with cobalamin C
deficiency. Ann Neurol 49:396–400
Prasad AN, Rupar CA, Prasad C (2011)Methyltetrahydrofolate reductase
(MTHFR)deficiency and infantile epilepsy. Brain Dev 33:758–769
Profitlich L, Kirmse B, Wasserstein MP, Diaz G, Srivastava S (2009a)
Resolution of cor pulmonale after medical management in a patient
with cblC-type methylmalonic aciduria and homocystinuria: a case
report. Cases J 30:8603
Profitlich LE, Kirmse B,Wasserstein MP, Diaz GA, Srivastava S (2009b)
High prevalence of structural heart disease in children with cblC-
type methylmalonic aciduria and homocystinuria. Mol Genet Metab
98:344–348
Rahmandar MH, Bawcom A, Romano ME, Hamid R (2014) Cobalamin
C deficiency in an adolescent with altered mental status and anorex-
ia. Pediatrics 134:e1709–1714
Refsum H, Grindflek AW, Ueland PM et al (2004) Screening for
serum total homocysteine in newborn children. Clin Chem 50:
1769–1784
Regland B, Johansson BV, Gottfries CG (1994) Homocysteinemia and
schizophrenia as a case of methylation deficiency. J Neural Transm
Gen Sect 98:143–152
Ribes A, Briones P, Vilaseca MA et al (1990) Methylmalonic aciduria
with homocystinuria: biochemical studies, treatment, and clinical
course of a Cbl-C patient. Eur J Pediatr 149:412–415
Ricci D, Pane M, Deodato F et al (2005) Assessment of visual function in
children with methylmalonic aciduria and homocystinuria.
Neuropediatrics 36:181–185
RobbRM,Dowton SB, Fulton AB, Levy HL (1984) Retinal degeneration
in vitamin B12 disorder associated with methylmalonic aciduria and
sulfur amino acid abnormalities. Am J Ophthalmol 97:691–696
Ronge E, Kiellman (1996) Long term treatment with betaine in methy-
lenetetrahydrofolate reductase deficiency. Arch Dis Child 74:239–
241
Rosenblatt DS, Cooper BA, Schmutz SM, Zaleski WA, Casey RE (1985)
Prenatal vitamin B12 therapy of a fetus with methylcobalamin defi-
ciency (cobalamin E disease). Lancet 18:1127–1129
Rosenblatt DS, Laframboise R, Pichette J, Langevin P, Cooper BA, Costa
(1986) New disorder of vitamin B12 metabolism (cobalamin F)
presenting as methylmalonic aciduria. Pediatrics 78:51–54
Rosenblatt DS, Aspler AL, Shevell MI, Pletcher BA, Fenton WA,
Seashore MR (1997) Clinical heterogeneity and prognosis in com-
bined methylmalonic aciduria and homocystinuria (cblC). J Inherit
Metab Dis 20:528–538
Rossi A, Cerone R, Biancheri R et al (2001) Early-onset combined
methylmalonic aciduria and homocystinuria: neuroradiologic find-
ings. AJNR Am J Neuroradiol 22:554–563
Roze E, Gervais D, Demeret S et al (2003) Neuropsychiatric disturbances
in presumed late-onset cobalamin C disease. Arch Neurol 60:1457–
1462
Ruiz-Mercado M, Vargas MT, Pérez de Soto I et al (2015) Methionine
synthase reductase deficiency (CblE): a report of two patients and a
n o v e l m u t a t i o n . H e m a t o l o g y d o i : 1 0 . 1 1 7 9 /
1607845415Y.0000000017
Russo P, Doyon J, Sonsino E, Ogier H, Saudubray JM (1992) A congen-
ital anomaly of vitamin B12 metabolism: a study of three cases.
Hum Pathol 23:504–512
Rutsch F, Gailus S, Miousse IR et al (2009) Identification of a putative
lysosomal cobalamin exporter altered in the cblF defect of vitamin
B12 metabolism. Nat Genet 41:234–239
Scalabrino G, Veber D, Mutti E (2007) New pathogenesis of the
cobalamin-deficient neuropathy. Med Secoli 19:9–18
Schiff M, Blom HJ (2012) Treatment of inherited homocystinurias.
Neuropediatrics 43:295–304
Schiff M, Benoist JF, Tilea B, Royer N, Giraudier S, Ogier de Baulny H
(2011) Isolated remethylation disorders: do our treatments benefit
patients? J Inherit Metab Dis 34:137–145
Schimel AM,MetsMB (2006) The natural history of retinal degeneration
in association with cobalamin C (cbl C) disease. Ophthalmic Genet
27:9–14
Scolamiero E, Villani GR, Ingenito L et al (2014) Maternal vitamin B12
deficiency detected in expanded newborn screening. Clin Biochem
47:312–317
Schwahn BC, Hafner D, Hohlfeld T, Balkenhol N, LaryeaMD,Wendel U
(2003) Pharmacokinetics of oral betaine in healthy subjects and
patients with homocystinuria. Br J Clin Pharmacol 55(1):6–13
Selzer RR, Rosenblatt DS, Laxova R, Hogan K (2003) Adverse effect of
nitrous oxide in a child with 5,10-methylenetetrahydrofolate reduc-
tase deficiency. N Engl J Med 349:45–50
Sharma AP, Greenberg CR, Prasad AN, Prasad C (2007) Hemolytic ure-
mic syndrome (HUS) secondary to cobalamin C (cblC) disorder.
Pediatr Nephrol 22:2097–2103
Shih VE, Axel SM, Tewksbury JC, Watkins D, Cooper BA, Rosenblatt
DS (1989) Defective lysosomal release of vitamin B12 (cb1F): a
hereditary cobalamin metabolic disorder associated with sudden
death. Am J Med Genet 33:555–563
Shinnar S, Singer HS (1984) Cobalamin C mutation (methylmalonic
aciduria and homocystinuria) in adolescence. A treatable cause of
dementia and myelopathy. N Engl J Med 311:451–454
Sibani S, Christensen B, O’Ferrall E et al (2000) Characterization of six
novel mutations in the methylenetetrahydrofolate reductase
(MTHFR) gene in patients with homocystinuria. Hum Mutat 15:
280–287
Smith DL, Bodamer OA (2002) Practical management of combined
methylmalonicaciduria and homocystinuria. J Child Neurol 17:
353–356
Smith SE, Kinney HC, Swoboda KJ, Levy HL (2006) Subacute com-
bined degeneration of the spinal cord in cblC disorder despite treat-
ment with B12. Mol Genet Metab 88:138–145
J Inherit Metab Dis
Spector R (1979) Affinity of folic acid for the folate-binding protein of
choroid plexus. Arch Biochem Biophys 194:632–634
Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of
serum cystathionine levels in patients with cobalamin and folate
deficiency. Blood 81:3404–3413
Stabler SP, Korson M, Jethva R et al (2013) Metabolic profiling of total
homocysteine and related compounds in hyperhomocysteinemia:
utility and limitations in diagnosing the cause of puzzling
thrombophilia in a family. JIMD Rep 11:149–63
Steen C, Rosenblatt DS, Scheying H, Braeuer HC, Kohlschütter A (1997)
Cobalamin E (cblE) disease: a severe neurological disorder with
megaloblastic anaemia, homocystinuria and low serum methionine.
J Inherit Metab Dis 20:705–706
Strauss KA, Morton DH, Puffenberger EG et al (2007) Prevention of
brain disease from severe 5,10 methyltetrahydrofolate reductase de-
ficiency. Mol Genet Metab 91:165–175
Stucki M, Coelho D, Suormala T, Burda P, Fowler B, Baumgartner MR
(2012) Molecular mechanisms leading to three different phenotypes
in the cblD defect of intracellular cobalamin metabolism. Hum Mol
Genet 21:1410–1418
Suormala T, Gamse G, Fowler B (2002) 5,10-methylenetetrahydrofolate
reductase (MTHFR) assay in the forward direction: residual activity
in MTHFR deficiency. Clin Chem 48:835–843
Suormala T, Baumgartner MR, Coelho D et al (2004) The CbD defect
causes either isolated or combinated deficiency of Methylcobalamin
and adenosylcobalamin synthesis. J Biol Chem 279:42742–42749
Surtees R, Leonard J, Austin S (1991) Association of demyelination with
deficiency of cerebrospinal fluid S-adenosylmethionine in inborn
errors of methyl-transfer pathway. Lancet 338:1550–1554
Tallur KK, Johnson DA, Kirk JM, Sandercock PA, Minns RA (2005)
Folate-induced reversal of leukoencephalopathy and intellectual de-
cline in methylene-tetrahydrofolate reductase deficiency: variable
response in siblings. Dev Med Child Neurol 47:53–56
Tanpaiboon P, Sloan JL, Callahan PF et al (2013) Noncompaction of the
ventricular myocardium and hydrops fetalis in cobalamin C disease.
JIMD Rep 10:33–38
Thauvin-Robinet C, Roze E, Couvreur G et al (2008) The adolescent and
adult form of cobalamin C disease: clinical and molecular spectrum.
J Neurol Neurosurg Psychiatry 79:725–728
Tomaske M, Bosk A, Heinemann MK et al (2001) CblC/D defect com-
bined with haemodynamically highly relevant VSD. J Inherit Metab
Dis 24:511–512
Tonetti C, Ruivard M, Rieu V, Zittoun J, Giraudier S (2002) Severe
methylenetetrahydrofolate reductase deficiency revealed by a
pulmonary embolism in a young adult. Br J Haematol 119:
397–379
Tonetti C, Saudubray JM, Echenne B, Landrieu P, Giraudier S, Zittoun J
(2003) Relations between molecular and biological abnormalities in
11 families from siblings affected with methylenetetrahydrofolate
reductase deficiency. Eur J Pediatr 162:466–475
Tortorelli S, Turgeon CT, Lim JS et al (2010) Two-tier approach to the
newborn screening of methylenetetrahydrofolate reductase deficien-
cy and other remethylation disorders with tandem mass spectrome-
try. J Pediatr 157:271–275
Traboulsi EI, Silva JC, Geraghty MT, Maumenee IH, Valle D, GreenWR
(1992) Ocular histopathologic characteristics of cobalamin C type
vitamin B12 defect with methylmalonic aciduria and
homocystinuria. Am J Ophthalmol 113:269–280
Trakadis YJ, Alfares A, Bodamer OA, Buyukavci M, Christodoulou J,
Connor P (2014) Update on transcobalamin deficiency: clinical pre-
sentation, treatment and outcome. J Inherit Metab Dis 37:461–473
Trefz FK, Scheible D, Frauendienst-Egger G et al (2016) Successful
intrauterine treatment of a patient with cobalamin C defect. Mol
Genet Metab Rep 6:55–59. doi:10.1016/j.ymgmr.2016.01.005.
eCollection
Tsai AC, Morel CF, Scharer G et al (2007) Late-onset combined
homocystinuria and methylmalonic aciduria (cblC) and neuropsy-
chiatric disturbance. Am J Med Genet A 143A:2430–2434
TsangBL, Devine OJ, Cordero AM et al (2015) Assessing the association
between the methylenetetrahydrofolate reductase (MTHFR)
677C>T polymorphism and blood folate concentrations: a system-
atic review andmeta-analysis of trials and observational studies. Am
J Clin Nutr 101:1286–1294
Tsina EK,Marsden DL,HansenRM, FultonAB (2005)Maculopathy and
retinal degeneration in cobalamin C methylmalonic aciduria and
homocystinuria. Arch Ophthalmol 123:1143–1146
Ucar SK, Koroğlu OA, Berk O et al (2010) Titration of betaine therapy to
optimize therapy in an infant with 5,10-methylenetetrahydrofolate
reductase deficiency. Eur J Pediatr 169:241–243
Urbón Artero A, Aldana Gómez J, Reig Del Moral C, Nieto Conde C,
Merinero Cortés B (2002) Neonatal onset methylmalonic aciduria
and homocystinuria: biochemical and clinical improvement with
betaine therapy. An Esp Pediatr 56:337–341
Urreizti R, Moya-García AA, Pino-Ángeles A et al (2010) Molecular char-
acterization of five patients with homocystinuria due to severe meth-
ylenetetrahydrofolate reductase deficiency. Clin Genet 78:441–448
Van Hove JL, Van Damme-Lombaerts R, Grünewald S et al (2002)
Cobalamin disorder Cbl-C presenting with late-onset thrombotic
microangiopathy. Am J Med Genet 111:195–201
Vilaseca MA, Vilarinho L, Zavadakova P et al (2003) CblE type of
homocystinuria: mild clinical phenotype in two patients homozygous
for a novelmutation in theMTRRgene. J InheritMetabDis 26:361–369
Visy JM, Le Coz P, Chadefaux B et al (1991) Homocystinuria due to 5,
10-methylenetetrahydrofolate reductase deficiency revealed by
stroke in adult siblings. Neurology 41:1313–1315
Waggoner DJ, Ueda K, Mantia C, Dowton SB (1998) Methylmalonic
aciduria (cblF): case report and response to therapy. Am J Med
Genet 79:373–375
Walk D, Kang SS, Horwitz A (1994) Intermittent encephalopathy, revers-
ible nerve conduction slowing, and MRI evidence of cerebral white
matter disease in methylenetetrahydrofolate reductase deficiency.
Neurology 44:344–347
Wang F, Han L, Yang Yet al (2010) Clinical, biochemical, and molecular
analysis of combined methylmalonic acidemia and hyperhomocys-
teinemia (cblC type) in China. J Inherit Metab Dis 33:S435–S442
WangX, SunW,YangY, Jia J, Li C (2012) A clinical and gene analysis of
late-onset combined methylmalonic aciduria and homocystinuria,
cblC type, in China. J Neurol Sci 15:155–159
Wang Q, Liu J, Liu YP et al (2014) Methylenetetrahydrofolate reductase
deficiency-induced schizophrenia in a school-age boy. Zhongguo
Dang Dai Er Ke Za Zhi 16:62–66
Watkins D, Rosenblatt DS (1989) Functional methionine synthase defi-
ciency (cblE and cblG): clinical and biochemical heterogeneity. Am
J Med Genet 34:427–434
Watkins D, Rosenblatt DS (2012) Update and new concepts in vitamin
responsive disorders of folate transport and metabolism. J Inherit
Metab Dis 35:665–670
Weisfeld-Adams JD, Bender HA, Miley-Åkerstedt A et al (2013)
Neurologic and neurodevelopmental phenotypes in young children
with early-treated combined methylmalonic acidemia and
homocystinuria, cobalamin C type. Mol Genet Metab 110:241–247
Weisfeld-Adams JD, Mc Court EA, Diaz GA, Oliver SC (2015) Ocular
disease in the cobalamin C defect: a review of the literature and a
suggested framework for clinical surveillance. Mol Genet Metab
114:537–546
Whitehead VM (2006) Acquired and inherited disorders of cobalamin
and folate in children. Br J Haematol 134:125–136
Wong D, Tortorelli S, Bishop L et al (2016) Outcomes of four patients
with homocysteine remethylation disorders detected by newborn
screening. Genet Med 18:162–167
J Inherit Metab Dis
Wu S, Gonzalez-Gomez I, Coates T, Yano S (2005) Cobalamin C disease
presenting with hemophagocytic lymphohistiocytosis. Pediatr
Hematol Oncol 22:717–721
Yaghmai R, Kashani AH, Geraghty MT et al (2002) Progressive cerebral
edema associated with highmethionine levels and betaine therapy in
a patient with cystathionine beta-synthase (CBS) deficiency. Am J
Med Genet 108:57–63
Yamada K, Gravel RA, Toraya T, Matthews RG (2006) Human methio-
nine synthase reductase is a molecular chaperone for human methi-
onine synthase. Proc Natl Acad Sci U S A 103(25):9476–9481
Yu HC, Sloan JL, Scharer G et al (2013) An X-linked cobalamin disorder
caused by mutations in transcriptional coregulator HCFC1. Am J
Hum Genet 93:506–514
Zavadáková P, Fowler B, Suormala T et al (2005) cblE type of
homocystinuria due to methionine synthase reductase deficiency:
functional correction by minigene expression. Hum Mutat 25:239–
247
Zsengellér ZK, Aljinovic N, Teot LA et al (2014) Methylmalonic
acidemia: a megamitochondrial disorder affecting the kidney.
Pediatr Nephrol 29:2139–2146
J Inherit Metab Dis
